Navigational tip: click on "leads to" or the ID column to navigate to the KE Relationship.

KE Relationships

Id	Upstream Event	Relationship Type	Downstream Event
5	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells	leads to	Reduction, Plasma 17beta-estradiol concentrations
9	Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity	leads to	Decreased, Mitochondrial fatty acid beta-oxidation
11	AchE Inhibition	leads to	ACh Synaptic Accumulation
16	Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways	leads to	Altered, Cardiovascular development/function
17	Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways	leads to	Up Regulation, CYP1A1
18	Activation, AhR	leads to	Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways
19	Activation, AhR	leads to	Up Regulation, CYP1A1
23	Alkylation, DNA	leads to	Increase, Heritable mutations in offspring
24	Alkylation, DNA	leads to	N/A, Inadequate DNA repair
25	Alkylation, DNA	leads to	Increase, Mutations
31	Agonism, Androgen receptor	leads to	Reduction, Gonadotropins, circulating concentrations
32	Agonism, Androgen receptor	leads to	Reduction, Testosterone synthesis by ovarian theca cells
33	N/A, Androgen receptor, Antagonism	leads to	Altered, Transcription of genes by AR
35	N/A, Androgen receptor, Antagonism	leads to	Alteration, Wnt pathway
36	Reduction, Angiogenesis	leads to	Impairment, Endothelial network
43	Decrease, Aromatase (Cyp19a1)	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
45	Inhibition, Aromatase	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
51	Increased Cholinergic Signaling	leads to	Decrease, Population trajectory
59	Reduction, Ca and HCO3 transport to shell gland	leads to	Reduction, Eggshell thickness
60	Increase, Ca++ (intracellular)	leads to	Disruption, Mitochondrial electron transport chain
61	Inhibition, Ca++ ATPase	leads to	Increase, Ca++ (intracellular)
62	Decreased, Calcium influx	leads to	Impairment, Learning and memory
66	Up Regulation, CD36	leads to	Increase, FA Influx
67	Cell injury/death	leads to	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
68	Cell injury/death	leads to	Activation, Stellate cells
69	Proliferation, Cell proliferation in the absence of cytotoxicity	leads to	Hyperplasia, Hyperplasia
70	Induction, Chitin degradation and resorption	leads to	Induction, Pre-mature molting
77	Activation, ChREBP	leads to	Synthesis, De Novo FA
82	Accumulation, Collagen	leads to	N/A, Liver fibrosis
88	N/A, Covalent binding to protein, possibly lysine residue	leads to	Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
93	Production, Critical Metabolites (CGA 330050 and CGA 265307)	leads to	Induction, Liver “Dysfunctional” Changes by CGA 330050
94	Reduction, Cumulative fecundity and spawning	leads to	Decrease, Population trajectory
95	Inhibition, Cyclooxygenase activity	leads to	Reduction, Prostaglandin E2 concentration
96	Up Regulation, CYP1A1	leads to	Peptide Oxidation
104	Up Regulation, CYP1B1	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
108	Release, Cytokine	leads to	Increase, Inflammation
110	Synthesis, De Novo FA	leads to	Accumulation, Triglyceride
116	Increase, EcR agonism	leads to	Induction, Chitin degradation and resorption
123	Reduction, Eggshell thickness	leads to	N/A, Reproductive failure
125	Impairment, Endothelial network	leads to	Insufficiency, Vascular
126	Agonism, Estrogen receptor	leads to	Altered, Reproductive behaviour
127	Agonism, Estrogen receptor	leads to	Impaired development of, Reproductive organs
128	Agonism, Estrogen receptor	leads to	Increase, Vitellogenin synthesis in liver
129	Antagonism, Estrogen receptor	leads to	Reduction, Vitellogenin synthesis in liver
132	Increase, FA Influx	leads to	Accumulation, Triglyceride
133	Activation, FAS	leads to	Synthesis, De Novo FA
135	Decrease, Fecundity	leads to	Decline, Population
136	N/A, Gap	leads to	Reduction, Ca and HCO3 transport to shell gland
143	Reduction, Gonadotropins, circulating concentrations	leads to	Reduction, Testosterone synthesis by ovarian theca cells
144	Depletion, GSH	leads to	N/A, Oxidative stress
146	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)	leads to	Peptide Oxidation
147	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)	leads to	Up Regulation, TGFbeta1 expression
154	Decreased, HSD17B10 expression	leads to	Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity
158	Hyperplasia, Hyperplasia	leads to	Promotion, Hepatocelluar carcinoma
159	Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307	leads to	Induction, Sustained Hepatotoxicity
164	N/A, Inadequate DNA repair	leads to	Increase, Mutations
168	N/A, Interferences with SH-/selen-proteins	leads to	Depletion, GSH
169	Increase, Liver and splenic hemosiderosis	leads to	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
170	Induction, Liver “Dysfunctional” Changes by CGA 330050	leads to	Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
172	Activation, Long term AHR receptor driven direct and indirect gene expression changes	leads to	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
173	Activation, LXR	leads to	Up Regulation, CD36
174	Activation, LXR	leads to	Activation, ChREBP
175	Activation, LXR	leads to	Activation, FAS
176	Activation, LXR	leads to	Activation, SCD-1
177	Activation, LXR	leads to	Activation, SREBP-1c
182	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number	leads to	N/A, Cyanosis occurs
188	Disruption, Mitochondrial electron transport chain	leads to	Decrease, Mitochondrial ATP production
189	Disruption, Mitochondrial electron transport chain	leads to	Increase, ROS production
190	Decreased, Mitochondrial fatty acid beta-oxidation	leads to	Accumulation, Fatty acid
196	Abnormal, Morphogenesis	leads to	Increased, Lethality
197	Abnormal, Morphogenesis	leads to	Increased, Structural malformations
198	Increase, Mortality	leads to	Decrease, Fecundity
199	Increase, Mortality	leads to	Decline, Population
200	Increased Mortality	leads to	Decline, Population
202	Increase, Mutations	leads to	Increase, Heritable mutations in offspring
203	Altered, Neuroanatomy	leads to	Altered, Neurophysiology
207	N/A, Neurodegeneration	leads to	Neuroinflammation
208	Neuroinflammation	leads to	N/A, Neurodegeneration
210	N/A, Neuronal dysfunction	leads to	Neuroinflammation
212	Decreased, Nitric Oxide	leads to	Decreased, Long-term potentiation (LTP)
213	Inhibition, NMDARs	leads to	Decreased, Calcium influx
214	Inhibition, NMDARs	leads to	Impairment, Learning and memory
215	Inhibition, NMDARs	leads to	N/A, Neuronal dysfunction
228	Binding of antagonist, NMDA receptors	leads to	Impairment, Learning and memory
229	Binding of antagonist, NMDA receptors	leads to	Inhibition, NMDARs
236	Peptide Oxidation	leads to	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
239	N/A, Oxidative stress	leads to	N/A, Neuronal dysfunction
240	Propagation, Oxidative stress	leads to	Down Regulation, Gulcose-6-phosphate dehydrogenase
241	Propagation, Oxidative stress	leads to	Damaging, Red blood cells; hemolysis
242	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	leads to	Altered regulation, Alpha hemoglobin
243	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	leads to	Formation, Formation of hemoglobin adducts
244	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	leads to	Propagation, Oxidative stress
245	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	leads to	Damaging, Red blood cells; hemolysis
248	Bile accumulation, Pathological condition	leads to	Activation of specific nuclear receptors, Transcriptional change
252	Reduction, Plasma 17beta-estradiol concentrations	leads to	Reduction, Vitellogenin synthesis in liver
253	Reduction, Plasma 17beta-estradiol concentrations	leads to	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
254	Increase, Plasma vitellogenin concentrations	leads to	Increase, Renal pathology due to VTG deposition
255	Reduction, Plasma vitellogenin concentrations	leads to	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
256	demethylation, PPARg promoter	leads to	Decrease, Aromatase (Cyp19a1)
257	Decreased, PPAR-alpha activation	leads to	Decreased, HSD17B10 expression
259	Decreased, PPAR-beta activation	leads to	Decreased, HSD17B10 expression
260	Decreased, PPAR-gamma activation	leads to	Decreased, HSD17B10 expression
261	Induction, Pre-mature molting	leads to	Decrease, Fecundity
262	Induction, Pre-mature molting	leads to	Increase, Mortality
263	Induction, Pre-mature molting	leads to	Increased Mortality
266	Feminisation or incomplete development, Primary and accessory male sex organs	leads to	N/A, Impairment of reproductive capacity
268	Reduction, Prostaglandin E2 concentration	leads to	N/A, Gap
269	Alkylation, Protein	leads to	Cell injury/death
271	Alkylation, Protein	leads to	Peptide Oxidation
272	Increase, RBC congestion in liver	leads to	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
276	Production, Reactive oxygen species	leads to	Peptide Oxidation
277	Damaging, Red blood cells; hemolysis	leads to	Increase, Liver and splenic hemosiderosis
278	Damaging, Red blood cells; hemolysis	leads to	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
279	Damaging, Red blood cells; hemolysis	leads to	Increase, RBC congestion in liver
280	Increase, Renal pathology due to VTG deposition	leads to	Altered, Larval development
282	Increase, ROS production	leads to	Decreased, Nitric Oxide
283	Increase, ROS production	leads to	Increased, Oxidative damage
284	Activation, SCD-1	leads to	Synthesis, De Novo FA
287	Binding, SH-/selen-proteins	leads to	N/A, Interferences with SH-/selen-proteins
294	Activation, SREBP-1c	leads to	Synthesis, De Novo FA
295	Activation, Stellate cells	leads to	Accumulation, Collagen
296	Increased, Structural malformations	leads to	Increased, Lethality
298	Induction, Sustained Cell Proliferation	leads to	Formation, Liver tumor
299	Induction, Sustained Hepatotoxicity	leads to	Induction, Sustained Cell Proliferation
301	Activation/Proliferation, T-cells	leads to	N/A, Allergic contact dermatitis on challenge
302	Reduction, Testosterone synthesis by ovarian theca cells	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
303	Up Regulation, TGFbeta1 expression	leads to	Accumulation, Collagen
304	Up Regulation, TGFbeta1 expression	leads to	Activation, Stellate cells
305	TH synthesis, Decreased	leads to	T4 in serum, Decreased
309	Thyroperoxidase, Inhibition	leads to	TH synthesis, Decreased
312	T4 in serum, Decreased	leads to	T4 in neuronal tissue, Decreased
315	Reduction, Vitellogenin synthesis in liver	leads to	Reduction, Plasma vitellogenin concentrations
316	Altered, Transcription of genes by AR	leads to	Feminisation or incomplete development, Primary and accessory male sex organs
317	Altered, Transcription of genes by AR	leads to	Alteration, Wnt pathway
319	Activation of specific nuclear receptors, Transcriptional change	leads to	Cholestasis, Pathology
321	Accumulation, Triglyceride	leads to	Damaging, Mitochondria
324	N/A, Unknown	leads to	Proliferation, Cell proliferation in the absence of cytotoxicity
329	Insufficiency, Vascular	leads to	Abnormal, Morphogenesis
330	Binding, VEGF-A	leads to	Decreased, VegfR2
331	Binding, VEGF-A	leads to	Inhibition, VegfR2
332	Production, VEGF-A	leads to	Binding, VEGF-A
333	Production, VEGF-A	leads to	Decreased, VegfR2
334	Decreased, VegfR2	leads to	Inhibition, VegfR2
335	Inhibition, VegfR2	leads to	Reduction, Angiogenesis
336	Increase, Vitellogenin synthesis in liver	leads to	Increase, Plasma vitellogenin concentrations
337	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development	leads to	Reduction, Cumulative fecundity and spawning
338	Alteration, Wnt pathway	leads to	Feminisation or incomplete development, Primary and accessory male sex organs
340	Activation, Pre-MIE: Metabolism of AFB1	leads to	Formation, Pro-mutagenic DNA Adducts
342	Increased, Induced Mutations in Critical Genes	leads to	Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
343	Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H	leads to	Tumorigenesis, Hepatocellular carcinoma
344	Formation, Pro-mutagenic DNA Adducts	leads to	Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
345	Formation, Pro-mutagenic DNA Adducts	leads to	Tumorigenesis, Hepatocellular carcinoma
346	Increased, Induced Mutations in Critical Genes	leads to	Tumorigenesis, Hepatocellular carcinoma
347	Decreased, Calcium influx	leads to	BDNF, Reduced
348	BDNF, Reduced	leads to	Aberrant, Dendritic morphology
350	Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci	leads to	Tumorigenesis, Hepatocellular carcinoma
351	Increased, Induced Mutations in Critical Genes	leads to	Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
352	Formation, Pro-mutagenic DNA Adducts	leads to	Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
353	BDNF, Reduced	leads to	Cell injury/death
354	BDNF, Reduced	leads to	Reduced, Presynaptic release of glutamate
355	Cell injury/death	leads to	Synaptogenesis, Decreased
356	Aberrant, Dendritic morphology	leads to	Synaptogenesis, Decreased
357	Reduced, Presynaptic release of glutamate	leads to	Synaptogenesis, Decreased
358	Synaptogenesis, Decreased	leads to	Neuronal network function, Decreased
359	Neuronal network function, Decreased	leads to	Impairment, Learning and memory
360	Binding of agonist, NMDARs	leads to	Overactivation, NMDARs
361	Overactivation, NMDARs	leads to	Increased, Intracellular Calcium overload
362	Increased, Intracellular Calcium overload	leads to	N/A, Mitochondrial dysfunction 1
363	N/A, Mitochondrial dysfunction 1	leads to	Cell injury/death
364	Cell injury/death	leads to	N/A, Neurodegeneration
365	Cell injury/death	leads to	Neuroinflammation
366	Thyroperoxidase, Inhibition	leads to	T4 in serum, Decreased
368	N/A, Neurodegeneration	leads to	Neuronal network function, Decreased
369	Activation, PPARα	leads to	Decrease, Steroidogenic acute regulatory protein (STAR)
370	Activation, PPARα	leads to	Decrease, Translocator protein (TSPO)
376	Covalent Binding, Protein	leads to	Response, Keratinocytes
377	Covalent Binding, Protein	leads to	Activation, Dendritic Cells
378	Response, Keratinocytes	leads to	Activation, Dendritic Cells
379	Activation, Dendritic Cells	leads to	Activation/Proliferation, T-cells
380	Response, Keratinocytes	leads to	Activation/Proliferation, T-cells
383	Thyroperoxidase, Inhibition	leads to	Cognitive Function, Decreased
384	Altered, Neurophysiology	leads to	Cognitive Function, Decreased
385	Activation, Glucocorticoid Receptor	leads to	Induction, IKB inhibitory protein
386	Induction, IKB inhibitory protein	leads to	Inhibition, Nuclear factor kappa B (NF-kB)
387	Inhibition, Nuclear factor kappa B (NF-kB)	leads to	Suppression, Inflammatory cytokines
388	Suppression, Inflammatory cytokines	leads to	Decreased, Lymphocytes
389	Decreased, Lymphocytes	leads to	Increased, Disease susceptibility
390	Decreased, Lymphocytes	leads to	Suppression, Immune system
392	Reduction, Plasma 17beta-estradiol concentrations	leads to	irregularities, ovarian cycle
393	irregularities, ovarian cycle	leads to	Decrease, Fertility
394	irregularities, ovarian cycle	leads to	impaired, Fertility
395	demethylation, PPARg promoter	leads to	reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
396	reduction in ovarian granulosa cells, Aromatase (Cyp19a1)	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
398	Increase proliferation, Leydig cell	leads to	Hyperplasia, Leydig cell
399	Decrease, Translocator protein (TSPO)	leads to	Reduction, Testosterone synthesis in Leydig cells
402	Metabolism of AFB1, Production of Reactive Electrophiles	leads to	Formation, Pro-mutagenic DNA Adducts
403	T4 in serum, Decreased	leads to	Cognitive Function, Decreased
405	Malformation, Male reproductive tract	leads to	impaired, Fertility
411	demethylation, PPARg promoter	leads to	Up Regulation, CD36
428	Increased Mortality	leads to	Decreased, Population trajectory
432	Increased, Atrioventricular block and bradycardia	leads to	Increased Mortality
433	Respiratory distress/arrest	leads to	Increased Mortality
434	Increased Cholinergic Signaling	leads to	Increased Mortality
436	Decrease, Steroidogenic acute regulatory protein (STAR)	leads to	Reduction, Cholesterol transport in mitochondria
437	Decrease, Translocator protein (TSPO)	leads to	Reduction, Cholesterol transport in mitochondria
438	Reduction, Cholesterol transport in mitochondria	leads to	Reduction, Testosterone synthesis in Leydig cells
439	Reduction, Testosterone synthesis in Leydig cells	leads to	Reduction, testosterone level
442	Inhibition, Na+/I- symporter (NIS)	leads to	Thyroidal Iodide, Decreased
443	Thyroidal Iodide, Decreased	leads to	T4 in serum, Decreased
444	T4 in neuronal tissue, Decreased	leads to	BDNF, Reduced
445	BDNF, Reduced	leads to	Down Regulation, K-Cl co-transporter 2 (KCC2)
446	Down Regulation, K-Cl co-transporter 2 (KCC2)	leads to	Delay, Developmental GABA shift
447	Delay, Developmental GABA shift	leads to	Synaptogenesis, Decreased
448	BDNF, Reduced	leads to	Synaptogenesis, Decreased
449	AchE Inhibition	leads to	Increased, Atrioventricular block and bradycardia
450	AchE Inhibition	leads to	Respiratory distress/arrest
451	AchE Inhibition	leads to	Increased Cholinergic Signaling
452	AchE Inhibition	leads to	Increased Mortality
453	AchE Inhibition	leads to	Decreased, Population trajectory
454	ACh Synaptic Accumulation	leads to	Increased, Atrioventricular block and bradycardia
456	ACh Synaptic Accumulation	leads to	Increased Cholinergic Signaling
457	Increased Cholinergic Signaling	leads to	Respiratory distress/arrest
459	ACh Synaptic Accumulation	leads to	AchE Inhibition
460	Reduction, testosterone level	leads to	Increase, Luteinizing hormone (LH)
461	Increase, Luteinizing hormone (LH)	leads to	Increase proliferation, Leydig cell
462	Hyperplasia, Leydig cell	leads to	impaired, Fertility
470	Inhibition, Mitochondrial fatty acid beta-oxidation	leads to	Accumulation, Liver lipid
471	Suppression, VLDL secretion	leads to	Accumulation, Liver lipid
472	Accumulation, Fatty acid	leads to	Accumulation, Triglyceride
473	Activation, AhR	leads to	Inhibition, Mitochondrial fatty acid beta-oxidation
474	Accumulation, Triglyceride	leads to	Accumulation, Liver lipid
475	Inhibition, Mitochondrial fatty acid beta-oxidation	leads to	Accumulation, Fatty acid
476	Suppression, Constitutive androstane receptor, NR1l3	leads to	Activation, LXR
477	Suppression, Constitutive androstane receptor, NR1l3	leads to	demethylation, PPARg promoter
479	Activation, LXR	leads to	Activation, SREBF1
482	Activation, SREBF1	leads to	Increased, De Novo FA synthesis
483	Activation, ChREBP	leads to	Increased, De Novo FA synthesis
484	Increased, De Novo FA synthesis	leads to	Increased, Triglyceride formation
486	Increased, Triglyceride formation	leads to	Increased, Liver Steatosis
487	demethylation, PPARg promoter	leads to	Activation, SREBF1
489	Activation, SREBF1	leads to	Up Regulation, SCD-1
490	Activation, LXR	leads to	Up Regulation, FAS
491	Activation, LXR	leads to	Up Regulation, SCD-1
492	Up Regulation, FAS	leads to	Increased, De Novo FA synthesis
493	Up Regulation, SCD-1	leads to	Increased, Triglyceride formation
495	Activation, AhR	leads to	Up Regulation, CD36
496	Activation, AhR	leads to	Increased, FA Influx
499	Activation, AhR	leads to	Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
501	Up Regulation, CD36	leads to	Increased, FA Influx
502	Accumulation, Fatty acid	leads to	Accumulation, Liver lipid
503	Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)	leads to	Accumulation, Fatty acid
504	Increased, FA Influx	leads to	Accumulation, Triglyceride
505	Increased, FA Influx	leads to	Accumulation, Fatty acid
506	Activation, AhR	leads to	Up Regulation, LDLR (low density lipoprotein receptor)
507	Up Regulation, LDLR (low density lipoprotein receptor)	leads to	Increased, LDL uptake
508	Increased, LDL uptake	leads to	Accumulation, Fatty acid
509	Activation, AhR	leads to	Suppression, VLDL secretion
510	Activation, LXR	leads to	Inhibition, PPAR alpha
511	Inhibition, PPAR alpha	leads to	Inhibition, Mitochondrial fatty acid beta-oxidation
512	Increased, De Novo FA synthesis	leads to	Accumulation, Fatty acid
514	Accumulation, Fatty acid	leads to	Increased, Triglyceride formation
515	Accumulation, Fatty acid	leads to	Increased, Liver Steatosis
516	Activation, LXR	leads to	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
517	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)	leads to	Increased, De Novo FA synthesis
518	Activation, PXR/SXR	leads to	Inhibition, FoxA2
519	Inhibition, FoxA2	leads to	Down Regulation, CPT1A
520	Down Regulation, CPT1A	leads to	Decreased, Mitochondrial fatty acid beta-oxidation
523	Inhibition, FoxA2	leads to	Down Regulation, HMGCS2
524	Down Regulation, HMGCS2	leads to	Decreased, Ketogenesis
526	Activation, PXR/SXR	leads to	Up Regulation, SCD-1
529	Activation, PXR/SXR	leads to	Up Regulation, CD36
532	Activation, NRF2	leads to	Activation, NR1H4
533	Activation, NR1H4	leads to	Activation, SHP
534	Activation, NR1H4	leads to	Activation, PPARα
535	Activation, PPARα	leads to	Activation, LXR alpha
537	Decreased, DHB4/HSD17B4	leads to	Inhibition, Mitochondrial fatty acid beta-oxidation
538	Inhibition, Mitochondrial fatty acid beta-oxidation	leads to	Increased, Liver Steatosis
541	inflammation	leads to	Activation, AKT2
544	Decrease, Ovulation	leads to	Reduction, Cumulative fecundity and spawning
547	Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts	leads to	Increased, Induced Mutations in Critical Genes
548	Formation, Pro-mutagenic DNA Adducts	leads to	Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
549	Increased, Induced Mutations in Critical Genes	leads to	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
550	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)	leads to	Tumorigenesis, Hepatocellular carcinoma
551	Formation, Pro-mutagenic DNA Adducts	leads to	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
552	Inhibition, Na+/I- symporter (NIS)	leads to	TH synthesis, Decreased
558	Reduced, Food storage	leads to	Decrease, Number of worker bees
559	Decrease, Number of worker bees	leads to	Death/Failure, Colony
562	Reduced, Food storage	leads to	impaired, Larval development
563	impaired, Larval development	leads to	Death/Failure, Colony
564	Impairment, Learning and memory	leads to	Abnormal, Roll change within caste
565	Abnormal, Roll change within caste	leads to	Reduced, Brood care
566	Reduced, Brood care	leads to	impaired, Larval development
567	Increase, Energetic demands and therefore metabolic stress	leads to	Increased, Appetite and hunger
568	Increased, Appetite and hunger	leads to	Abnormal, Foraging activity and behavior
569	Abnormal, Foraging activity and behavior	leads to	Decrease, Number of worker bees
570	Suppression, Immune system	leads to	Increased, Viral susceptibility
571	Increased, Viral susceptibility	leads to	impaired, Development
572	impaired, Development	leads to	Decrease, Number of worker bees
573	Decrease, Number of worker bees	leads to	impaired, Hive thermoregulation
574	impaired, Hive thermoregulation	leads to	Death/Failure, Colony
575	Increased, Viral susceptibility	leads to	Abnormal, Foraging activity and behavior
576	Decreased, Glucose oxidase enzyme activity	leads to	Decreased, Hydrogen peroxide production
577	Decreased, Hydrogen peroxide production	leads to	Reduced, Antiseptic incorporated in food
578	Reduced, Antiseptic incorporated in food	leads to	Abnormal, Roll change within caste
579	Abnormal, Roll change within caste	leads to	Reduced, Food storage
580	Abnormal, Roll change within caste	leads to	Decrease, Number of worker bees
581	Activation, Nicotinic acetylcholine receptor	leads to	N/A, Mitochondrial dysfunction 1
582	N/A, Mitochondrial dysfunction 1	leads to	Neuronal network function, Decreased
583	Impairment, Learning and memory	leads to	Abnormal, Foraging activity and behavior
584	Abnormal, Foraging activity and behavior	leads to	Reduced, Food storage
585	Inhibition, sodium channel	leads to	Decreased, Sodium conductance 1
586	Decreased, Sodium conductance 1	leads to	Reduced, swimming speed
587	Reduced, swimming speed	leads to	Reduced, feeding 1
588	Reduced, swimming speed	leads to	Increased, predation
589	Reduced, feeding 1	leads to	Increased, predation
590	Inhibition, sodium channel	leads to	Increased, Atrioventricular block and bradycardia
591	Increased, Atrioventricular block and bradycardia	leads to	Respiratory distress/arrest
592	Respiratory distress/arrest	leads to	N/A, hypoxia
593	N/A, hypoxia	leads to	Increased, amputations
594	Decreased, Sodium conductance 1	leads to	Increased, Atrioventricular block and bradycardia
595	Increased, predation	leads to	Reduced, survival
596	Reduced, feeding 1	leads to	Reduced, survival
597	Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel	leads to	Decreased, Sodium conductance 1
603	modulation, sodium channel	leads to	prolonged, Depolarization of neuronal membrane
604	prolonged, Depolarization of neuronal membrane	leads to	Overactivation, Neuronotransmitter release
605	Overactivation, Neuronotransmitter release	leads to	Overactivation, muscle contraction
606	Overactivation, muscle contraction	leads to	Increased, Ataxia, paralysis, or hyperactivity
607	Increased, Ataxia, paralysis, or hyperactivity	leads to	Increased Mortality
608	Reduction, testosterone level	leads to	Malformation, Male reproductive tract
617	Decreased, Mitochondrial fatty acid beta-oxidation	leads to	Increased, Liver Steatosis
630	Occurrence, A paroxysmal depolarizing shift	leads to	Occurrence, Epileptic seizure
634	Decreased, Neuronal network function in adult brain	leads to	Impairment, Learning and memory
635	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	leads to	Increased, serotonin (5-HT) 1
636	Increased, serotonin (5-HT) 1	leads to	Increase, cilia movement
637	Increase, cilia movement	leads to	Increased, locomotion
638	Increased, locomotion	leads to	Increase, predation
639	Increase, cilia movement	leads to	Increased, foot detachment
640	Increased, serotonin (5-HT) 1	leads to	Increased, muscular waves in foot
641	Increased, muscular waves in foot	leads to	Increased, locomotion
642	Increased, muscular waves in foot	leads to	Increased, foot detachment
643	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	leads to	Increased, serotonin (5-HT)
644	Increased, serotonin (5-HT)	leads to	Decreased, anxiety
645	Decreased, anxiety	leads to	Decreased, sheltering
646	Decreased, sheltering	leads to	Increased, predation
647	N/A, Neurodegeneration	leads to	Decreased, Neuronal network function in adult brain
649	Decrease, histaminergic neuron excitation	leads to	N/A, sedation
650	N/A, sedation	leads to	Decreased, locomotion
651	Decreased, locomotion	leads to	Increased, predation
654	Increased, predation	leads to	Decreased, survival
656	Synaptogenesis, Decreased	leads to	Neuroinflammation
658	Activation, Nicotinic acetylcholine receptor	leads to	Desensitization, Nicotinic acetylcholine receptor
659	Desensitization, Nicotinic acetylcholine receptor	leads to	Neuronal network function, Decreased
660	N/A, Mitochondrial dysfunction 1	leads to	Overwhelmed, Mitochondrial DNA repair mechanisms
661	Overwhelmed, Mitochondrial DNA repair mechanisms	leads to	Accumulation, Damaged mitochondrial DNA
662	Accumulation, Damaged mitochondrial DNA	leads to	Accelerated, Aging
663	Accelerated, Aging	leads to	Decrease, Number of worker bees
664	N/A, Mitochondrial dysfunction 1	leads to	impaired, Thoracic shivering
665	impaired, Thoracic shivering	leads to	impaired, Hive thermoregulation
666	Binding at picrotoxin site, iGABAR chloride channel	leads to	Reduction, Ionotropic GABA receptor chloride channel conductance
667	Reduction, Ionotropic GABA receptor chloride channel conductance	leads to	Reduction, Neuronal synaptic inhibition
670	Inhibition, Cyclooxygenase activity	leads to	Reduced, Prostaglandin F2alpha synthesis, ovary
671	Reduced, Prostaglandin F2alpha synthesis, ovary	leads to	Reduced, Prostaglandin F2alpha concentration, plasma
672	Reduced, Prostaglandin F2alpha concentration, plasma	leads to	Reduced, Spawning behavior
673	Reduced, Spawning behavior	leads to	Reduced, Ability to attract spawning mates
674	Reduced, Ability to attract spawning mates	leads to	Reduced, Reproductive Success
675	Reduced, Reproductive Success	leads to	Decrease, Population trajectory
678	Reduced, Prostaglandin F2alpha concentration, plasma	leads to	Reduced, Pheromone release
679	Reduced, Pheromone release	leads to	Reduced, Ability to attract spawning mates
681	Inhibition, Cyclooxygenase activity	leads to	Decreased, Prostaglandin F2alpha synthesis, ovary
682	Decreased, Prostaglandin F2alpha synthesis, ovary	leads to	Reduced, Prostaglandin F2alpha concentration, plasma
683	Reduction, Neuronal synaptic inhibition	leads to	Generation, Amplified excitatory postsynaptic potential (EPSP)
684	Generation, Amplified excitatory postsynaptic potential (EPSP)	leads to	Occurrence, A paroxysmal depolarizing shift
685	Reduced, Prostaglandins, ovary	leads to	Decrease, Ovulation
686	Inhibition, Cyclooxygenase activity	leads to	Reduced, Prostaglandins, ovary
687	Decrease, Ovulation	leads to	Reduced, Reproductive Success
689	Inhibition, Cyclooxygenase activity	leads to	Reduced, Prostaglandin E2 concentration, hypothalamus
690	Reduced, Prostaglandin E2 concentration, hypothalamus	leads to	Reduced, Gonadotropin releasing hormone, hypothalamus
691	Reduced, Gonadotropin releasing hormone, hypothalamus	leads to	Reduced, Luteinizing hormone (LH), plasma
692	Reduced, Luteinizing hormone (LH), plasma	leads to	Reduced, Maturation inducing steroid, plasma
693	Reduced, Maturation inducing steroid, plasma	leads to	Reduced, Maturation inducing steroid receptor signalling, oocyte
694	Reduced, Maturation inducing steroid receptor signalling, oocyte	leads to	Increased, cyclic adenosine monophosphate
695	Increased, cyclic adenosine monophosphate	leads to	Reduced, Reproductive Success
696	Increased, cyclic adenosine monophosphate	leads to	Reduced, Meiotic prophase I/metaphase I transition, oocyte
697	Reduced, Meiotic prophase I/metaphase I transition, oocyte	leads to	Reduced, Reproductive Success
698	Reduced, Maturation inducing steroid receptor signalling, oocyte	leads to	Upregulated, Spindle assembly checkpoint protein Mad2-oocyte
699	Upregulated, Spindle assembly checkpoint protein Mad2-oocyte	leads to	Increased, Chromosome misseggregation
700	Increased, Chromosome misseggregation	leads to	Reduced, Reproductive Success
701	impaired, ion channels	leads to	Altered, Action Potential
702	Altered, Action Potential	leads to	Increased, cardiac arrthymia
703	Increased, cardiac arrthymia	leads to	Increased Mortality
706	Increased, Binding of chemicals to 2u (serum)	leads to	Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)
707	Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)	leads to	Increase, Cytotoxicity (renal tubular cell)
708	Increase, Cytotoxicity (renal tubular cell)	leads to	Increase, Regenerative cell proliferation (tubular epithelial cells)
711	Activation, Constitutive androstane receptor	leads to	Increase, cell proliferation (hepatocytes)
714	Binding, Tubulin	leads to	Disruption, Microtubule dynamics
715	Disruption, Microtubule dynamics	leads to	Disorganization, Spindle
716	Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme	leads to	Increased, Induction of pyruvate dehydrogenase (PDH)
723	Altered, Chromosome number	leads to	Increase, Aneuploid offspring
724	Binding, Tubulin	leads to	Altered, Chromosome number
726	Increase, Necrosis (terminal bronchiolar cells)	leads to	Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)
727	Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)	leads to	Increase, Hyperplasia (terminal bronchiolar cells)
728	Increase, Hyperplasia (terminal bronchiolar cells)	leads to	Increase, Adenomas/carcinomas (bronchioloalveolar)
729	Decreased, Androgen receptor activity	leads to	Decreased, Testosterone binding to androgen receptor (hypothalamus)
730	Decreased, Testosterone binding to androgen receptor (hypothalamus)	leads to	Increase, Hyperplasia (Leydig cells)
731	Increase, Hyperplasia (Leydig cells)	leads to	Increase, Leydig cell tumors
732	Increase, Dopaminergic activity	leads to	Decreased, Prolactin
733	Decreased, Prolactin	leads to	Increased, Estrogen receptor (ER) activity
734	Increased, Estrogen receptor (ER) activity	leads to	Decreased, Progesterone from corpus luteum
737	Disorganization, Spindle	leads to	Altered, Meiotic chromosome dynamics
738	Altered, Meiotic chromosome dynamics	leads to	Altered, Chromosome number
741	Increase, Thyroid-stimulating hormone (TSH)	leads to	Increase, Hypertrophy and proliferation (follicular cell)
742	Increase, Hypertrophy and proliferation (follicular cell)	leads to	Increase, Hyperplasia (follicular cells)
743	Increase, Hyperplasia (follicular cells)	leads to	Increase, Adenomas/carcinomas (follicular cell)
744	Decreased, Testosterone binding to androgen receptor (hypothalamus)	leads to	Increased, Luteinizing hormone (LH)
745	Increased, Luteinizing hormone (LH)	leads to	Increase, Hyperplasia (Leydig cells)
746	T4 in neuronal tissue, Decreased	leads to	Hippocampal gene expression, Altered
747	Hippocampal gene expression, Altered	leads to	Hippocampal anatomy, Altered
748	Hippocampal Physiology, Altered	leads to	Cognitive Function, Decreased
749	Hippocampal anatomy, Altered	leads to	Hippocampal Physiology, Altered
750	Activation, 5HT2c	leads to	N/A, Unknown
751	N/A, Unknown	leads to	Increased, Kidney Failure
752	Activation, Glutamate-gated chloride channel	leads to	Increased, Chloride conductance
755	hyperpolarisation, neuron	leads to	N/A, Ataxia, paralysis, or hyperactivity
756	Increased Mortality	leads to	Decreased, population 1
757	N/A, Ataxia, paralysis, or hyperactivity	leads to	Increased Mortality
758	Increased, Chloride conductance	leads to	hyperpolarisation, neuron
759	Neuroinflammation	leads to	Synaptogenesis, Decreased
760	Increase, Regenerative cell proliferation (tubular epithelial cells)	leads to	Increase, Hyperplasia (renal tubular cells)
761	Increase, Hyperplasia (renal tubular cells)	leads to	Increase, Adenomas/carcinomas (renal tubular)
762	Increased, Induction of pyruvate dehydrogenase (PDH)	leads to	Increase, Oxidative metabolism
763	Increase, Oxidative metabolism	leads to	Peptide Oxidation
764	Peptide Oxidation	leads to	Increase, hepatocellular adenomas and carcinomas
765	Peptide Oxidation	leads to	Increase, Cytotoxicity
766	Increase, Cytotoxicity	leads to	Increase, hepatocellular adenomas and carcinomas
767	Increase, Cytotoxicity (club cells)	leads to	Increase, Necrosis (terminal bronchiolar cells)
768	Decreased, Uptake of inorganic iodide	leads to	Decrease, Serum thyroid hormone (T4/T3)
769	Decrease, Serum thyroid hormone (T4/T3)	leads to	Increase, Thyroid-stimulating hormone (TSH)
770	Increase, Dopaminergic activity	leads to	Increase, Endometrial adenocarcinomas
771	Increase, Hyperplasia (glandular epithelial cells of endometrium)	leads to	Increase, Endometrial adenocarcinomas
772	Decreased, Progesterone from corpus luteum	leads to	Increase, Hyperplasia (glandular epithelial cells of endometrium)
773	Increase, cell proliferation (hepatocytes)	leads to	Increase, Preneoplastic foci (hepatocytes)
774	Increase, Preneoplastic foci (hepatocytes)	leads to	Increase, hepatocellular adenomas and carcinomas
775	Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme	leads to	Increased, Plasma tyrosine
776	Increased, Plasma tyrosine	leads to	Increase, Cytotoxicity (corneal cells)
777	Increase, Cytotoxicity (corneal cells)	leads to	Increase, Inflammation (corneal cells)
778	Increase, Inflammation (corneal cells)	leads to	Increase, Regenerative cell proliferation (corneal cells)
779	Increase, Regenerative cell proliferation (corneal cells)	leads to	Increase, Papillomas/carcinomas (squamous cells)
780	Increase, Cytotoxicity (epithelial cells)	leads to	Increase, Inflammation
781	Increase, Inflammation	leads to	Increase, Regenerative cell proliferation (forestomach epithelial cells)
782	Increase, Regenerative cell proliferation (forestomach epithelial cells)	leads to	Increase, Hyperplasia (forestomach epithelial cells)
783	Increase, Hyperplasia (forestomach epithelial cells)	leads to	Increase, Papillomas/carcinomas (squamous cells)
784	Increase, Cytotoxicity (tubular epithelial cells)	leads to	Increase, Regenerative cell proliferation (tubular epithelial cells)
785	Increase, Regenerative cell proliferation (tubular epithelial cells)	leads to	Increase, Hyperplasia (tubular epithelial cells)
786	Increase, Hyperplasia (tubular epithelial cells)	leads to	Increase, Adenomas/carcinomas (renal tubular)
787	Activation, Androgen receptor	leads to	Increase, cell proliferation (hepatocytes)
788	Increase, Cytotoxicity (hepatocytes)	leads to	Increase, Regenerative cell proliferation (hepatocytes)
789	Increase, Regenerative cell proliferation (hepatocytes)	leads to	Increase, Preneoplastic foci (hepatocytes)
790	Thyroperoxidase, Inhibition	leads to	Decrease, Incorporation of active iodide into iodotyrosines
791	Decrease, Incorporation of active iodide into iodotyrosines	leads to	Decrease, Serum thyroid hormone (T4/T3)
792	Inhibition, 5α-reductase activity	leads to	Decrease, Bioactivation of testosterone
793	Decrease, Bioactivation of testosterone	leads to	Increased, Leutinizing hormone (LH)
794	Increased, Leutinizing hormone (LH)	leads to	Increase, Hyperplasia (Leydig cells)
795	Increase, Urinary bladder calculi	leads to	Increase, Cytotoxicity (urothelial cells)
796	Increase, Cytotoxicity (urothelial cells)	leads to	Increase, Regenerative cell proliferation (urothelial cells)
797	Increase, Regenerative cell proliferation (urothelial cells)	leads to	Increase, Hyperplasia (urothelial)
798	Increase, Hyperplasia (urothelial)	leads to	Increase, Adenomas/carcinomas (urothelial)
799	Inhibition, Prolyl hydroxylases	leads to	Increased, HIF-1 heterodimer
800	Increased, HIF-1 heterodimer	leads to	Decreased, Aromatase (Cyp19a1) mRNA
801	Decreased, Aromatase (Cyp19a1) mRNA	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
802	modulation, Unknown	leads to	Increased, HIF-1 alpha transcription
803	Increased, HIF-1 alpha transcription	leads to	Increased, HIF-1 heterodimer
804	Inhibition, HMG-CoA reductase	leads to	Decreased, mevalonate
805	Decreased, mevalonate	leads to	Decreased, cholesterol
806	Decreased, cholesterol	leads to	Decreased, Testosterone
807	Decreased, Testosterone	leads to	malformed, Male reproductive tract
808	malformed, Male reproductive tract	leads to	Decrease, Fertility
809	TH synthesis, Decreased	leads to	Decreased, Thyroxine (T4) in serum
810	TH synthesis, Decreased	leads to	Increased, Serum creatinine
811	Decreased, Thyroxine (T4) in serum	leads to	Occurrence, Cytoplasmic vacuolization (Renal tubule)
812	Decreased, Thyroxine (T4) in serum	leads to	Occurrence, Cystic dilatation (renal tubule)
813	Increased, Serum creatinine	leads to	Occurrence, Cytoplasmic vacuolization (Renal tubule)
814	Increased, Serum creatinine	leads to	Occurrence, Cystic dilatation (renal tubule)
815	Decreased, Thyroxine (T4) in serum	leads to	Occurrence, Cytoplasmic vacuolization (podocyte)
816	Increased, Serum creatinine	leads to	Occurrence, Cytoplasmic vacuolization (podocyte)
817	Occurrence, Cytoplasmic vacuolization (Renal tubule)	leads to	Decreased, Glomerular filtration
818	Occurrence, Cytoplasmic vacuolization (Renal tubule)	leads to	Decreased, Renal plasma flow
819	Occurrence, Cytoplasmic vacuolization (Renal tubule)	leads to	Decreased, Sodium reabsorption
820	Occurrence, Cytoplasmic vacuolization (Renal tubule)	leads to	Decreased, Renal ability to dilute urine
821	Occurrence, Cystic dilatation (renal tubule)	leads to	Decreased, Glomerular filtration
822	Occurrence, Cystic dilatation (renal tubule)	leads to	Decreased, Renal plasma flow
823	Occurrence, Cystic dilatation (renal tubule)	leads to	Decreased, Sodium reabsorption
824	Occurrence, Cystic dilatation (renal tubule)	leads to	Decreased, Renal ability to dilute urine
825	Occurrence, Cytoplasmic vacuolization (podocyte)	leads to	Decreased, Glomerular filtration
826	Occurrence, Cytoplasmic vacuolization (podocyte)	leads to	Decreased, Renal plasma flow
827	Occurrence, Cytoplasmic vacuolization (podocyte)	leads to	Decreased, Sodium reabsorption
828	Occurrence, Cytoplasmic vacuolization (podocyte)	leads to	Decreased, Renal ability to dilute urine
829	Decreased, Glomerular filtration	leads to	Occurrence, Kidney toxicity
830	Decreased, Renal plasma flow	leads to	Occurrence, Kidney toxicity
831	Decreased, Sodium reabsorption	leads to	Occurrence, Kidney toxicity
832	Decreased, Renal ability to dilute urine	leads to	Occurrence, Kidney toxicity
833	Covalent Binding, Protein	leads to	Activation, Keratinocytes
834	Activation, Keratinocytes	leads to	Activation, Dendritic Cells
835	Activation/Proliferation, T-cells	leads to	sensitisation, skin
836	Inhibition, Phospholipase A	leads to	Damage, Lipid bilayer
837	Inhibition, Phospholipase A	leads to	Disturbance, Lysosomal function
838	Inhibition, Phospholipase A	leads to	Injury, Mitochondria
839	Damage, Lipid bilayer	leads to	Occurrence, Cytoplasmic vacuolization (hepatocyte)
840	Damage, Lipid bilayer	leads to	Occurrence, Ballooning degeneration (hepatocyte)
841	Damage, Lipid bilayer	leads to	Occurrence, Cytoplasmic vacuolization (Bile duct cell)
842	Damage, Lipid bilayer	leads to	Occurrence, Cytoplasmic vacuolization (kupffer cell)
843	Disturbance, Lysosomal function	leads to	Occurrence, Cytoplasmic vacuolization (hepatocyte)
844	Disturbance, Lysosomal function	leads to	Occurrence, Ballooning degeneration (hepatocyte)
845	Disturbance, Lysosomal function	leads to	Occurrence, Cytoplasmic vacuolization (Bile duct cell)
846	Disturbance, Lysosomal function	leads to	Occurrence, Cytoplasmic vacuolization (kupffer cell)
847	Injury, Mitochondria	leads to	Occurrence, Cytoplasmic vacuolization (hepatocyte)
848	Injury, Mitochondria	leads to	Occurrence, Ballooning degeneration (hepatocyte)
849	Injury, Mitochondria	leads to	Occurrence, Cytoplasmic vacuolization (Bile duct cell)
850	Injury, Mitochondria	leads to	Occurrence, Cytoplasmic vacuolization (kupffer cell)
851	Occurrence, Cytoplasmic vacuolization (hepatocyte)	leads to	Induction, Microvesicular fat
852	Occurrence, Cytoplasmic vacuolization (hepatocyte)	leads to	Formation, Mallory body
853	Occurrence, Ballooning degeneration (hepatocyte)	leads to	Induction, Microvesicular fat
854	Occurrence, Ballooning degeneration (hepatocyte)	leads to	Formation, Mallory body
855	Occurrence, Cytoplasmic vacuolization (Bile duct cell)	leads to	Induction, Microvesicular fat
856	Occurrence, Cytoplasmic vacuolization (Bile duct cell)	leads to	Formation, Mallory body
857	Occurrence, Cytoplasmic vacuolization (kupffer cell)	leads to	Induction, Microvesicular fat
858	Occurrence, Cytoplasmic vacuolization (kupffer cell)	leads to	Formation, Mallory body
859	Induction, Microvesicular fat	leads to	Formation, Liver fibrosis
860	Formation, Mallory body	leads to	Formation, Liver fibrosis
864	Oxidation, Uroporphyrinogen	leads to	Accumulation, Highly carboxylated porphyrins
865	Oxidation, Uroporphyrinogen	leads to	Inhibition, UROD
866	Accumulation, Highly carboxylated porphyrins	leads to	Uroporphyria
867	Inhibition, UROD	leads to	Oxidation, Uroporphyrinogen
868	Induction, CYP1A2/CYP1A5	leads to	Oxidation, Uroporphyrinogen
869	Activation, AhR	leads to	Induction, CYP1A2/CYP1A5
870	BDNF, Reduced	leads to	GABAergic interneurons, Decreased
871	GABAergic interneurons, Decreased	leads to	Synaptogenesis, Decreased
872	Thyroidal Iodide, Decreased	leads to	TH synthesis, Decreased
874	Activation, Long term AHR receptor driven direct and indirect gene expression changes	leads to	Changes/Inhibition, Cellular Homeostasis and Apoptosis
875	Activation, Long term AHR receptor driven direct and indirect gene expression changes	leads to	Alterations, Cellular proliferation / hyperplasia
876	Activation, Long term AHR receptor driven direct and indirect gene expression changes	leads to	Formation, Hepatocellular and Bile duct tumors
877	Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain	leads to	Decreased, PPARalpha transactivation of gene expression
878	Decreased, PPARalpha transactivation of gene expression	leads to	Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
879	Decreased, PPARalpha transactivation of gene expression	leads to	Decreased, Mitochondrial Fatty Acid Beta Oxidation
880	Decreased, PPARalpha transactivation of gene expression	leads to	Decreased, Ketogenesis (production of ketone bodies)
881	Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	leads to	Decreased, Mitochondrial Fatty Acid Beta Oxidation
882	Decreased, Mitochondrial Fatty Acid Beta Oxidation	leads to	Decreased, Ketogenesis (production of ketone bodies)
883	Decreased, Ketogenesis (production of ketone bodies)	leads to	Not Increased, Circulating Ketone Bodies
884	Not Increased, Circulating Ketone Bodies	leads to	Increased, Catabolism of Muscle Protein
885	Increased, Catabolism of Muscle Protein	leads to	Decreased, Body Weight
886	Decrease, Intracellular pH	leads to	Increase, Cytotoxicity
887	Increase, Cytotoxicity	leads to	Increase, Tissue Degeneration, Necrosis & Atrophy
888	Increase, Tissue Degeneration, Necrosis & Atrophy	leads to	Increase, Respiratory or Squamous Metaplasia
889	Increase, Respiratory or Squamous Metaplasia	leads to	Increase, Cell Proliferation
890	Increase, Cell Proliferation	leads to	Increased, Induced Mutations in Critical Genes
891	Increased, Induced Mutations in Critical Genes	leads to	Increase, Site of Contact Nasal Tumors
892	Increased, Intracellular Calcium overload	leads to	Decreased, Neuronal network function in adult brain
893	Increase, Cell Proliferation	leads to	Increase, Mutations in Critical Genes
894	Increase, Mutations in Critical Genes	leads to	Increase, Site of Contact Nasal Tumors
895	Increase, Cell Proliferation	leads to	Increase, Site of Contact Nasal Tumors
896	Activation, SHP	leads to	Inhibition, SREBP1c
899	Increase, Mutations	leads to	Increase, Cancer
901	Alkylation, DNA	leads to	Increase, Cancer
904	N/A, Mitochondrial dysfunction 1	leads to	Impaired, Proteostasis
905	Impaired, Proteostasis	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway
906	Neuroinflammation	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway
907	Degeneration of dopaminergic neurons of the nigrostriatal pathway	leads to	Neuroinflammation
908	N/A, Mitochondrial dysfunction 1	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway
910	Degeneration of dopaminergic neurons of the nigrostriatal pathway	leads to	Parkinsonian motor deficits
911	Disruption, Lysosome	leads to	Increase, ROS production
912	Increase, ROS production	leads to	N/A, Mitochondrial dysfunction 1
916	Infiltration, Inflammatory cells	leads to	Inflammation, Liver
919	Binding of agonist, Ionotropic glutamate receptors	leads to	Overactivation, NMDARs
921	Disruption, Lysosome	leads to	Peptide Oxidation
922	Peptide Oxidation	leads to	N/A, Mitochondrial dysfunction 1
923	Peptide Oxidation	leads to	Release, Cytokine
924	Cell injury/death	leads to	Release, Cytokine
925	Release, Cytokine	leads to	Infiltration, Inflammatory cytokines
926	Infiltration, Inflammatory cytokines	leads to	Inflammation, Liver
927	Inhibition, Bile Salt Export Pump (ABCB11)	leads to	Bile accumulation, Pathological condition
928	Bile accumulation, Pathological condition	leads to	Release, Cytokine
929	Increase, Inflammation	leads to	Cholestasis, Pathology
930	Bile accumulation, Pathological condition	leads to	Production, Reactive oxygen species
931	Production, Reactive oxygen species	leads to	Cholestasis, Pathology
932	Peptide Oxidation	leads to	Cholestasis, Pathology
933	Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)	leads to	Inhibition, NADH-ubiquinone oxidoreductase (complex I)
934	Inhibition, NADH-ubiquinone oxidoreductase (complex I)	leads to	N/A, Mitochondrial dysfunction 1
936	Activation, Epidermal Growth Factor Receptor	leads to	Decrease, Apoptosis of ciliated epithelial cells
939	Activation, Epidermal Growth Factor Receptor	leads to	Increase, Proliferation of goblet cells
942	Activation, Epidermal Growth Factor Receptor	leads to	Occurrence, Transdifferentiation of ciliated epithelial cells
943	Occurrence, Transdifferentiation of ciliated epithelial cells	leads to	Occurrence, Metaplasia of goblet cells
944	Increase, Proliferation of goblet cells	leads to	Goblet cell hyperplasia
946	Activation, Epidermal Growth Factor Receptor	leads to	Activation, Sp1
948	Peptide Oxidation	leads to	Oxidation, Glutathione
952	Decrease, GTPCH-1	leads to	Decrease, Tetrahydrobiopterin
953	Decrease, Tetrahydrobiopterin	leads to	Uncoupling, eNOS
954	Oxidation, Glutathione	leads to	S-Glutathionylation, eNOS
955	S-Glutathionylation, eNOS	leads to	Uncoupling, eNOS
956	Uncoupling, eNOS	leads to	Depletion, Nitric Oxide
958	Depletion, Nitric Oxide	leads to	Impaired, Vasodilation
961	Decrease, Apoptosis of ciliated epithelial cells	leads to	Occurrence, Transdifferentiation of ciliated epithelial cells
962	Activation, EGFR	leads to	Decrease, Apoptosis of ciliated epithelial cells
964	Activation, EGFR	leads to	Activation, Sp1
965	Activation, EGFR	leads to	Occurrence, Transdifferentiation of ciliated epithelial cells
970	Activation, EGFR	leads to	Increase, Proliferation of goblet cells
972	Activation, AhR	leads to	dimerization, AHR/ARNT
973	dimerization, AHR/ARNT	leads to	reduced dimerization, ARNT/HIF1-alpha
974	reduced dimerization, ARNT/HIF1-alpha	leads to	reduced production, VEGF
975	reduced production, VEGF	leads to	Impairment, Endothelial network
976	Impairment, Endothelial network	leads to	Altered, Cardiovascular development/function
977	Altered, Cardiovascular development/function	leads to	Increase, Pericardial edema
980	Peptide Oxidation	leads to	Decrease, GTPCH-1
982	Impaired, Vasodilation	leads to	Increase, Vascular Resistance
983	Increase, Vascular Resistance	leads to	Hypertension
984	Activation, AhR	leads to	Increase, Early Life Stage Mortality
986	Activation, EGFR	leads to	Increase, Mucin production
987	Activation, Sp1	leads to	Increase, Mucin production
988	Decrease, AKT/eNOS activity	leads to	Depletion, Nitric Oxide
989	Goblet cell hyperplasia	leads to	Hypersecretion, Mucus
990	Occurrence, Metaplasia of goblet cells	leads to	Hypersecretion, Mucus
991	Increase, Mucin production	leads to	Hypersecretion, Mucus
992	Peptide Oxidation	leads to	Decrease, AKT/eNOS activity
993	Disruption, Lysosome	leads to	N/A, Mitochondrial dysfunction 1
994	Release, Cytokine	leads to	Infiltration, Inflammatory cells
995	Changes/Inhibition, Cellular Homeostasis and Apoptosis	leads to	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
996	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects	leads to	Alterations, Cellular proliferation / hyperplasia
997	Alterations, Cellular proliferation / hyperplasia	leads to	Formation, Hepatocellular and Bile duct tumors
998	Increase, EcR agonism	leads to	Decrease, Circulating ETH
999	Increase, EcR agonism	leads to	Decreased, synthesis and secretion of molting fluid proteases
1000	Decrease, Circulating ETH	leads to	Increase, Incomplete ecdysis
1001	Decreased, synthesis and secretion of molting fluid proteases	leads to	Increase, Incomplete ecdysis
1002	Increase, Incomplete ecdysis	leads to	Increase, Mortality
1004	Increase, Mortality	leads to	Decreased, population 1
1007	Increase, EcR agonism	leads to	Decreased, Synthesis of molting fluid proteases
1008	Decrease, Circulating ETH	leads to	Decrease, Abdominal muscle contraction
1009	Decreased, Synthesis of molting fluid proteases	leads to	Decrease, Digestion of old cuticle
1010	Decrease, Abdominal muscle contraction	leads to	Increase, Incomplete ecdysis
1011	Decrease, Digestion of old cuticle	leads to	Increase, Incomplete ecdysis
1013	Increase, Mortality	leads to	Decreased, Population size
1015	Inhibition, Calcineurin Activity	leads to	Activation, Suppression of NFAT activation and hindrance of nuclear localization
1016	Activation, Suppression of NFAT activation and hindrance of nuclear localization	leads to	Interference, nuclear localization of NFAT
1017	Interference, nuclear localization of NFAT	leads to	Reduction, NFAT/AP-1 complex formation
1018	Reduction, NFAT/AP-1 complex formation	leads to	Suppression, Suppression in mixed lymphocyte reaction (MLR)
1019	Reduction, NFAT/AP-1 complex formation	leads to	Suppression, Suppression of T-cell dependent antibody response (TDAR)
1020	Reduction, NFAT/AP-1 complex formation	leads to	Impairment, T-cell dependent antibody response
1021	Reduction, NFAT/AP-1 complex formation	leads to	Relief, Relief of atopic dermatitis
1022	Reduction, NFAT/AP-1 complex formation	leads to	Increase, Increased susceptibility to infection
1023	Binding of antagonist, PPAR alpha	leads to	stabilization, PPAR alpha co-repressor
1024	stabilization, PPAR alpha co-repressor	leads to	Decreased, PPARalpha transactivation of gene expression
1025	Abnormal, Morphogenesis	leads to	Increased, Developmental Defects
1026	Inhibition, Deiodinase 2	leads to	Decreased, Triiodothyronine (T3) in serum
1027	Decreased, Triiodothyronine (T3) in serum	leads to	Reduced, Posterior swim bladder inflation
1028	Reduced, Posterior swim bladder inflation	leads to	Reduced, Swimming performance
1031	Reduced, Posterior swim bladder inflation	leads to	Reduced, Anterior swim bladder inflation
1032	Reduced, Anterior swim bladder inflation	leads to	Reduced, Hearing
1034	Reduced, Anterior swim bladder inflation	leads to	Reduced, Swimming performance
1035	Decreased, Triiodothyronine (T3) in serum	leads to	Reduced, Anterior swim bladder inflation
1036	Insufficiency, Vascular	leads to	Increased, Developmental Defects
1037	Inhibition, Deiodinase 1	leads to	Decreased, Triiodothyronine (T3) in serum
1039	T4 in serum, Decreased	leads to	Reduced, Anterior swim bladder inflation
1040	Thyroperoxidase, Inhibition	leads to	Reduced, Anterior swim bladder inflation
1042	Inhibition, Deiodinase 2	leads to	Reduced, Posterior swim bladder inflation
1043	Inhibition, Deiodinase 2	leads to	Reduced, Anterior swim bladder inflation
1044	Inhibition, Deiodinase 1	leads to	Reduced, Posterior swim bladder inflation
1045	Inhibition, Deiodinase 1	leads to	Reduced, Anterior swim bladder inflation
1047	Increased, Chloride influx	leads to	Increased, Inhibitory postsynaptic potential
1048	Increased, Inhibitory postsynaptic potential	leads to	Inhibition, Motor neuron activity
1049	Inhibition, Motor neuron activity	leads to	Induction, Somatic muscle paralysis
1050	Induction, Somatic muscle paralysis	leads to	Increased Mortality
1051	Activation, ionotropic GABA Receptor chloride channel	leads to	Increased, Chloride conductance
1052	Increased, Chloride conductance	leads to	Increased, Neuronal synaptic inhibition
1053	Increased, Neuronal synaptic inhibition	leads to	Increased, Inhibitory postsynaptic potential
1054	Increased, Inhibitory postsynaptic potential	leads to	Induction, Somatic muscle paralysis
1055	Induction, Somatic muscle paralysis	leads to	Inhibition, Feeding
1056	Inhibition, Feeding	leads to	Increased Mortality
1057	Activation, Glutamate-gated chloride channels	leads to	Increased, Chloride conductance
1058	Increased, Inhibitory postsynaptic potential	leads to	Induction, pharyngeal muscle paralysis
1059	Induction, pharyngeal muscle paralysis	leads to	Inhibition, Feeding
1061	Antagonism, Histamine Receptor (H2)	leads to	Decrease, histaminergic neuron excitation
1062	Formation, The binding of FK506 with FKBP12	leads to	Inhibition, Calcineurin Activity
1063	Increased, induction of UDPGT's in liver	leads to	Increased, T4/T3 catabolism
1064	Increased, T4/T3 catabolism	leads to	Decreased, serum T4/T3
1065	Decreased, serum T4/T3	leads to	Increased, Thyroid-stimulating hormone (TSH)
1066	Increased, Thyroid-stimulating hormone (TSH)	leads to	Increased, Hypertrophy and proliferation (follicular cell)
1067	Increased, Hypertrophy and proliferation (follicular cell)	leads to	Increased, Hyperplasia (follicular cells)
1068	Increased, Hyperplasia (follicular cells)	leads to	Increased Apoptosis, Adenomas/carcinomas (follicular cell)
1069	N/A, Neurodegeneration	leads to	Impairment, Learning and memory
1070	Inhibition, UROD	leads to	Accumulation, Highly carboxylated porphyrins
1071	Activation of specific nuclear receptors, PPAR-gamma activation	leads to	Increased, adipogenesis
1072	Activation of specific nuclear receptors, PPAR-gamma activation	leads to	Increased, secretion of local growth factors
1073	Increased, adipogenesis	leads to	Increased, secretion of local growth factors
1074	Increased, secretion of local growth factors	leads to	Increased, proliferation of mesenchymal cells
1075	Increased, secretion of local growth factors	leads to	Increased, IGF-1 (mouse)
1076	Increased, proliferation of mesenchymal cells	leads to	Increased, Firbrosarcoma
1077	Increased, proliferation of mesenchymal cells	leads to	Increased, liposarcoma
1078	Increased, proliferation of mesenchymal cells	leads to	Increased, hemagiosarcoma
1079	Activation, beta-2 adrenergic receptor	leads to	Increased activity, beta-2 adrenergic receptor
1080	Increased activity, beta-2 adrenergic receptor	leads to	relaxation, smooth muscle
1081	relaxation, smooth muscle	leads to	Proliferation/Clonal Expansion, smooth muscle
1082	Proliferation/Clonal Expansion, smooth muscle	leads to	Hypertrophy/hyperplasia, smooth muscle
1083	Hypertrophy/hyperplasia, smooth muscle	leads to	Promotion, mesovarian leiomyomas
1084	Decreased, Ovarian E2	leads to	Increased, secretion of GnRH from hypothalamus
1085	Decreased, Ovarian E2	leads to	Decrease, E2 blood concentrations at hypothalamus
1086	Suppression, Estrogen receptor (ER) activity	leads to	Decrease, E2 blood concentrations at hypothalamus
1087	Decrease, E2 blood concentrations at hypothalamus	leads to	Increased, secretion of GnRH from hypothalamus
1088	Increased, secretion of GnRH from hypothalamus	leads to	Increased, secrection of FSH from anterior pituitary
1089	Increased, secretion of GnRH from hypothalamus	leads to	Increased, secretion of LH from anterior pituitary
1090	Increased, secrection of FSH from anterior pituitary	leads to	Hyperplasia, ovarian stromal cells
1091	Increased, secrection of FSH from anterior pituitary	leads to	Hyperplasia, ovarian epithelium
1092	Increased, secretion of LH from anterior pituitary	leads to	Hyperplasia, ovarian stromal cells
1093	Hyperplasia, ovarian epithelium	leads to	Promotion, ovarian adenomas
1094	Hyperplasia, ovarian stromal cells	leads to	Promotion, ovarian granular cell tumors
1095	Increased, PPAR-alpha activation	leads to	Decreased, bile flow
1096	Increased, PPAR-alpha activation	leads to	Increased, cholestasis
1097	Increased, PPAR-alpha activation	leads to	Alteration, lipid metabolism
1098	prolonged, elevation of serun CCK	leads to	Increased, Cellular proliferation / hyperplasia of acinar cells
1099	Increased, Cellular proliferation / hyperplasia of acinar cells	leads to	Increased, Pancreatic acinar tumors
1100	Increased, cholestasis	leads to	prolonged, elevation of serun CCK
1101	Decreased, bile flow	leads to	Increased, cholestasis
1102	prepubertal increase, Estrogen receptor (ER) activity	leads to	Activation, estrogen receptor alpha
1103	Activation, estrogen receptor alpha	leads to	Promotion, SIX-1 postive basal-type progenitor cells
1104	Promotion, SIX-1 postive basal-type progenitor cells	leads to	Proliferation/Clonal Expansion, aberrant basal cells
1105	Proliferation/Clonal Expansion, aberrant basal cells	leads to	squamous metaplasia, aberrant basal cells
1106	squamous metaplasia, aberrant basal cells	leads to	Increased, Hyperplasia (glandular epithelial cells of endometrium)
1107	Increased, Hyperplasia (glandular epithelial cells of endometrium)	leads to	Increased, adenosquamous carcinomas of endometrium
1108	Decreased, GnRH pulsatility/release in hypothalamus	leads to	Decreased, LH Surge from anterior pituitary
1109	Decreased, LH Surge from anterior pituitary	leads to	interruption, Ovulation
1110	Decreased, LH Surge from anterior pituitary	leads to	prolonged, estrus
1111	prolonged, estrus	leads to	Increased, circulating estrogen levels
1112	prolonged, estrus	leads to	Increased, prolactin exposure
1113	Increased, circulating estrogen levels	leads to	Hyperplasia, Mammary gland
1114	Increased, prolactin exposure	leads to	Hyperplasia, Mammary gland
1115	Hyperplasia, Mammary gland	leads to	Increased, latency period
1116	Hyperplasia, Mammary gland	leads to	Increased, Adenomas/carcinomas (mammary)
1117	Increased, latency period	leads to	Increased, Adenomas/carcinomas (mammary)
1118	interruption, Ovulation	leads to	Increased, circulating estrogen levels
1119	Increased, circulating estrogen levels	leads to	Increased, lactotroph hyperplasia and hypertrophy
1120	Increased, lactotroph hyperplasia and hypertrophy	leads to	Increased, adenomas (pituitary)
1121	Decreased, Dopaminergic activity	leads to	Increased, prolactin secretion
1122	Increased, prolactin secretion	leads to	Increased, hyperplasia (mammary gland)
1123	Increased, hyperplasia (mammary gland)	leads to	Increased, latency period
1124	Increased, hyperplasia (mammary gland)	leads to	Increased, Adenomas/carcinomas (mammary)
1125	persistent, cytotoxicity (pleura or peritoneum)	leads to	Increased, inflammation
1126	persistent, cytotoxicity (pleura or peritoneum)	leads to	Increased, Oxidative Stress
1127	Increased, inflammation	leads to	Increased, secretion of local growth factors
1128	Increased, Oxidative Stress	leads to	Increased, secretion of local growth factors
1129	Increased, secretion of local growth factors	leads to	Increased, Cell Proliferation (mesothelium)
1130	Increased, Cell Proliferation (mesothelium)	leads to	Increased, mesotheliomas
1131	Inhibition, organic anion transporter 1 (OAT1)	leads to	Increased, blood uric acid concentration
1132	Increased, blood uric acid concentration	leads to	Occurrence, tophi (urate) deposition
1133	Occurrence, tophi (urate) deposition	leads to	Occurrence, renal proximal tubular necrosis
1134	Occurrence, renal proximal tubular necrosis	leads to	Increased, blood potassium concentration
1135	Increased, blood potassium concentration	leads to	Occurrence, cardiac arrthymia
1136	Occurrence, cardiac arrthymia	leads to	Increased Mortality
1137	Inhibition, Cyclooxygenase 1 activity	leads to	Decreased, Prostaglandin F2alpha concentration, plasma
1138	Decreased, Prostaglandin F2alpha concentration, plasma	leads to	Occurrence, renal ischemia
1139	Occurrence, renal ischemia	leads to	Occurrence, renal proximal tubular necrosis
1140	Increased, blood potassium concentration	leads to	Occurrence, cardiac arrhythmia
1141	Occurrence, cardiac arrhythmia	leads to	Increased Mortality
1142	Decreased, Thyroxine (T4) in tissues	leads to	Altered, Amphibian metamorphosis
1143	T4 in serum, Decreased	leads to	Decreased, Thyroxine (T4) in tissues
1144	Abnormal, Foraging activity and behavior	leads to	Weakened, Colony
1145	Weakened, Colony	leads to	Death/Failure, Colony
1146	Activation, Nicotinic acetylcholine receptor	leads to	Impairment, Learning and memory
1147	Activation, Nicotinic acetylcholine receptor	leads to	Abnormal, Foraging activity and behavior
1148	Abnormal, Foraging activity and behavior	leads to	Abnormal, Roll change within caste
1149	Abnormal, Roll change within caste	leads to	Weakened, Colony
1150	Abnormal, Foraging activity and behavior	leads to	Abnormal, Role change within caste
1151	Abnormal, Role change within caste	leads to	Weakened, Colony
1152	N/A, Mitochondrial dysfunction 1	leads to	impaired, Hive thermoregulation
1153	impaired, Hive thermoregulation	leads to	Weakened, Colony
1154	N/A, Mitochondrial dysfunction 1	leads to	Weakened, Colony
1155	Increased, Deformed Wing Virus levels	leads to	Weakened, Colony
1156	Occurrence, renal proximal tubular necrosis	leads to	Increased, blood uric acid concentration
1157	Increased, Energetic demands and therefore metabolic stress	leads to	Abnormal, Foraging activity and behavior
1158	Increased, blood uric acid concentration	leads to	Increased, Oxidative Stress
1159	Occurrence, renal ischemia	leads to	Increased, Oxidative Stress
1160	Increased, Oxidative Stress	leads to	Occurrence, renal proximal tubular necrosis
1161	Unknown, MIE	leads to	Increased, Reactive oxygen species
1162	Increased, Reactive oxygen species	leads to	Increased, Oxidative Stress
1163	Decreased, Thyroxine (T4) in tissues	leads to	Decreased, Triiodothyronine (T3) in tissues
1164	Decreased, Triiodothyronine (T3) in tissues	leads to	Altered, Amphibian metamorphosis
1165	Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo	leads to	Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
1166	Hemostasis, Depletion from blood of fully functional carboxylated clotting factors	leads to	Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur
1167	Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle	leads to	Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo
1168	Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur	leads to	Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
1169	Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)	leads to	Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis
1170	Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis	leads to	Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
1171	Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction	leads to	Impaired recruitment , Population trajectory
1172	Increased, serotonin (5-HT) 1	leads to	Increased, valve movement
1173	Increased, valve movement	leads to	Depletion, energy reserves
1174	Increased, valve movement	leads to	Increased, water retention in foot
1175	Increased, water retention in foot	leads to	Increased, foot detachment
1176	Increased, foot detachment	leads to	Depletion, energy reserves
1177	Increased, locomotion	leads to	Depletion, energy reserves
1178	Increase, cilia movement	leads to	premature, spawning 1
1179	premature, spawning 1	leads to	Decreased, Reproductive Success
1180	Decreased, Reproductive Success	leads to	Decline, Population
1181	Depletion, energy reserves	leads to	Delayed, Sexual maturity
1182	Delayed, Sexual maturity	leads to	Decreased, Reproductive Success
1183	Increased, foot detachment	leads to	Increase, predation
1184	Increase, predation	leads to	Decline, Population
1185	Depletion, energy reserves	leads to	Increase, predation
1186	Increased, serotonin (5-HT) 1	leads to	Decreased, gametogenesis
1187	Increase, cilia movement	leads to	premature, Spawning
1188	Decreased, gametogenesis	leads to	Decreased, Reproductive Success
1189	Increased, serotonin (5-HT) 1	leads to	Increased, locomotion
1190	Increase, Incomplete ecdysis	leads to	Increased Mortality
1191	Increased Mortality	leads to	Decreased, Population size
1192	Increased, serotonin (5-HT) 1	leads to	increased or inappropriate, mantel display
1193	increased or inappropriate, mantel display	leads to	Decreased, Reproductive Success
1194	Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p	leads to	Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei
1195	Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei	leads to	Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp
1196	Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp	leads to	Osteoporosis and vascular calcification, Bone deterioration
1197	Inhibition, Iodotyrosine deiodinase (IYD)	leads to	Thyroidal Iodide, Decreased
1198	Inhibition, Deiodinase 1	leads to	Decreased, Triiodothyronine (T3) in tissues
1199	Inhibition, Deiodinase 2	leads to	Decreased, Triiodothyronine (T3) in tissues
1200	Inhibition, Deiodinase 3	leads to	Increased, Triiodothyronine (T3) in tissues
1201	Increased, Triiodothyronine (T3) in tissues	leads to	Altered, Amphibian metamorphosis
1202	Inhibition, Pendrin	leads to	TH synthesis, Decreased
1203	Inhibition, Dual oxidase	leads to	TH synthesis, Decreased
1204	Activation, Hepatic nuclear receptor(s)	leads to	Increased, Hepatic thyroid hormone uptake/transport
1205	Activation, Hepatic nuclear receptor(s)	leads to	Induction, Upregulation of glucuronyltransferase activity
1206	Increased, Hepatic thyroid hormone uptake/transport	leads to	Increase, Biliary excretion TH glucuronide
1207	Increased, serotonin (5-HT)	leads to	Increased, mantel display
1208	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	leads to	Increased, cilia movement
1209	Increased, serotonin (5-HT)	leads to	Increased, cilia movement
1210	Increased, cilia movement	leads to	premature, Spawning
1211	premature, Spawning	leads to	Increased, Population
1212	Increased, serotonin (5-HT)	leads to	Increased, oocyte maturation
1213	Increased, oocyte maturation	leads to	Increased, Reproductive Success
1214	Increased, mantel display	leads to	Increased, Reproductive Success
1215	Increased, Reproductive Success	leads to	Increased, Population
1216	Increased, valve movement	leads to	Increased, water pumping
1217	Increase, cilia movement	leads to	Increased, water pumping
1218	Increase, cilia movement	leads to	Depletion, energy reserves
1219	increased or inappropriate, mantel display	leads to	Depletion, energy reserves
1220	increased or inappropriate, mantel display	leads to	induced, parturition
1221	induced, parturition	leads to	Decreased, Reproductive Success
1222	premature, Spawning	leads to	Decreased, Reproductive Success
1223	Increased, water retention in foot	leads to	Increased, valve movement
1224	Increased, water pumping	leads to	Increased, water retention in foot
1225	Increased, water pumping	leads to	premature, Spawning
1226	Increased, water pumping	leads to	induced, parturition
1227	Increased, valve movement	leads to	Increase, predation
1228	Increased, muscular waves in foot	leads to	Depletion, energy reserves
1229	Activation, PPARα	leads to	Increase, Phenotypic enzyme activity
1230	Increase, Phenotypic enzyme activity	leads to	Increase, cell proliferation (hepatocytes)
1231	Increase, Phenotypic enzyme activity	leads to	Increase, Clonal Expansion of Altered Hepatic Foci
1232	Increase, Clonal Expansion of Altered Hepatic Foci	leads to	Increase, hepatocellular adenomas and carcinomas
1233	Activation, PPARα	leads to	Increase, Genes involved in fatty acid oxidation
1234	Increase, Genes involved in fatty acid oxidation	leads to	Peptide Oxidation
1235	Activation, NADPH Oxidase	leads to	Peptide Oxidation
1236	Activation, PPARα	leads to	Activation, NADPH Oxidase
1237	Peptide Oxidation	leads to	Increase activation, Nuclear factor kappa B (NF-kB)
1238	Increase activation, Nuclear factor kappa B (NF-kB)	leads to	Increase, Phenotypic enzyme activity
1239	Increase, cell proliferation (hepatocytes)	leads to	Increase, Clonal Expansion of Altered Hepatic Foci
1240	Increase, Genes involved in fatty acid oxidation	leads to	Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
1241	Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	leads to	Peptide Oxidation
1242	Inhibition, sodium channel	leads to	Decreased, sodium conductance 2
1243	Decreased, sodium conductance 2	leads to	Decreased, Ionotropic GABA receptor chloride channel conductance
1244	Decreased, sodium conductance 2	leads to	Decreased, GABA release
1245	Decreased, GABA release	leads to	Decreased, Chloride conductance
1246	Activation, Estrogen receptor	leads to	Increased, ER binding to DNA (classical pathway)
1247	Increase, Cell Proliferation (Epithelial Cells)	leads to	Increased, Ductal Hyperplasia
1248	Decreased, Apoptosis (Epithelial Cells)	leads to	Increased, Ductal Hyperplasia
1249	Activation, Estrogen receptor	leads to	Increased, ER binding to T.F. to DNA (non-classical pathway)
1250	Increased, ER binding to DNA (classical pathway)	leads to	Increase, Cell Proliferation (Epithelial Cells)
1251	Increased, ER binding to T.F. to DNA (non-classical pathway)	leads to	Increase, Cell Proliferation (Epithelial Cells)
1252	Increased, Ductal Hyperplasia	leads to	N/A, Breast Cancer
1253	Binding, Immunophilins	leads to	Inhibition, Calcineurin Activity
1254	Inhibition, Calcineurin Activity	leads to	Suppression, IL-2 and IL-4 production
1255	Suppression, IL-2 and IL-4 production	leads to	Interference, nuclear localization of NFAT
1256	Reduction, NFAT/AP-1 complex formation	leads to	Suppression, Suppression of production of cytotoxic T-cells
1257	Reduction, NFAT/AP-1 complex formation	leads to	Suppression, Suppression of T-cell dependent antibody production
1258	Suppression, Suppression of production of cytotoxic T-cells	leads to	Impairment, T-cell dependent antibody response
1259	Suppression, Suppression of T-cell dependent antibody production	leads to	Increase, Increased susceptibility to infection
1260	Suppression, Suppression of production of cytotoxic T-cells	leads to	Increase, Increased susceptibility to infection
1261	Activation, Juvenile hormone receptor	leads to	Induction, Doublesex1 gene
1262	Induction, Doublesex1 gene	leads to	Induction, Male reproductive tract
1263	Induction, Male reproductive tract	leads to	Increased, Male offspring
1264	Increased, Male offspring	leads to	Decline, Population
1265	Decline, Population	leads to	Alteration, Food-web structures
1266	Increased, Proliferation (Endothelial cells)	leads to	Increased, Angiogenesis
1267	Increased, Migration (Endothelial Cells)	leads to	Increased, Angiogenesis
1268	Activation, Constitutive androstane receptor	leads to	Altered expression of hepatic CAR-dependent genes
1269	Altered expression of hepatic CAR-dependent genes	leads to	Increase, cell proliferation (hepatocytes)
1271	TRPA1 activation, TRPA1 Receptor	leads to	Opening of calcium channel, Calcium influx
1272	Opening of calcium channel, Calcium influx	leads to	Sensory Airway Irritation
1273	Sensory Airway Irritation	leads to	Cough, Dyspnea, Sneezing, Acute respiratory effect
1274	Opening of calcium channel, Calcium influx	leads to	Excitation, Trigeminal nerve excitation
1275	Excitation, Trigeminal nerve excitation	leads to	Cough, Dyspnea, Sneezing, Acute respiratory effect
1276	Excitation, Trigeminal nerve excitation	leads to	Increased Airway Hyper-responsiveness,Cough, Dyspnea
1277	Non-neuronal production of TNF, Epithelial irritation	leads to	Leukocyte infiltration
1278	Leukocyte infiltration	leads to	Respiratory irritability
1279	SP (Substance P) release, Local increase of SP	leads to	Non-neuronal production of TNF, Epithelial irritation
1280	Opening of calcium channel, Calcium influx	leads to	SP (Substance P) release, Local increase of SP
1281	TRPV1 activation, TRPV1	leads to	Opening of calcium channel, Calcium influx
1282	Oxidization of biomolecules, Lipid bilayer and cellular proteins	leads to	TRPA1 activation, TRPA1 Receptor
1283	Production of nerve growth factor , Epithelial irritation	leads to	SP (Substance P) release, Local increase of SP
1284	TRPA1 activation, TRPA1 Receptor	leads to	Non-neuronal production of IL-8/CXCL1, Epithelial irritation
1285	Oxidization of biomolecules, Lipid bilayer and cellular proteins	leads to	Generation of novel epitopes , Antigen presentation
1286	Oxidization of biomolecules, Lipid bilayer and cellular proteins	leads to	Production of nerve growth factor , Epithelial irritation
1287	Non-neuronal production of IL-8/CXCL1, Epithelial irritation	leads to	Opening of calcium channel, Calcium influx
1288	Non-neuronal production of TNF, Epithelial irritation	leads to	Opening of calcium channel, Calcium influx
1289	Generation of novel epitopes , Antigen presentation	leads to	Sensitization, Immune system
1290	Leukocyte infiltration	leads to	Sensitization, Immune system
1291	Oxidation	leads to	Generation of novel epitopes , Antigen presentation
1292	Oxidation	leads to	TRPA1 activation, TRPA1 Receptor
1293	Oxidation	leads to	Production of nerve growth factor , Epithelial irritation
1294	Activation, Estrogen receptor	leads to	Increased, Non-genomic signaling
1295	Increased, Non-genomic signaling	leads to	Increased, ER binding to T.F. to DNA (non-classical pathway)
1296	Increased, ER binding to DNA (classical pathway)	leads to	Altered, Gene Expression
1297	Increased, ER binding to T.F. to DNA (non-classical pathway)	leads to	Altered, Gene Expression
1298	Altered, Gene Expression	leads to	Altered, Protein Production
1299	Altered, Protein Production	leads to	Increased, Oxidative Stress
1300	Increased, Oxidative Stress	leads to	Increase, DNA Damage
1301	Increase, DNA Damage	leads to	Altered, Gene Expression
1302	Increased, Non-genomic signaling	leads to	Altered, Gene Expression
1303	Altered, Protein Production	leads to	Increased, Proliferation (Endothelial cells)
1304	Altered, Protein Production	leads to	Decreased, Apoptosis (Epithelial Cells)
1305	Altered, Protein Production	leads to	Increased, Motility
1306	Increased, Motility	leads to	Increased, Invasion
1307	Activation, Estrogen receptor	leads to	Increased, Second Messenger Production
1308	Increased, Second Messenger Production	leads to	Increased, Non-genomic signaling
1309	Desensitization, Nicotinic acetylcholine receptor	leads to	Altered, Ca2+-calmodulin activated signal transduction
1310	Altered, Ca2+-calmodulin activated signal transduction	leads to	Impairment, Learning and memory
1311	N/A, Mitochondrial dysfunction 1	leads to	Altered, Ca2+-calmodulin activated signal transduction
1312	Goblet cell hyperplasia	leads to	Increase, Mucin production
1313	Occurrence, Metaplasia of goblet cells	leads to	Increase, Mucin production
1314	Chronic, Mucus hypersecretion	leads to	Decrease, Lung function
1315	Increase, Mucin production	leads to	Chronic, Mucus hypersecretion
1316	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	leads to	Increased, muscular waves in foot
1317	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	leads to	Increased, valve movement
1318	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	leads to	Increase, cilia movement
1319	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	leads to	increased mantel display
1320	Increased, valve movement	leads to	induced spawning
1321	Increase, cilia movement	leads to	induced spawning
1322	increased mantel display	leads to	Induced parturition
1323	Induced parturition	leads to	Decreased, Reproductive Success
1324	induced spawning	leads to	Decreased, Reproductive Success
1325	induced spawning	leads to	Increased, Reproductive Success
1326	Induced parturition	leads to	Increased, Reproductive Success
1327	Increased, serotonin (5-HT)	leads to	Increased, valve movement
1328	Increased, oocyte maturation	leads to	induced spawning
1329	Increased, cilia movement	leads to	induced spawning
1330	Binding, topoisomerase II	leads to	MLL translocation
1331	MLL translocation	leads to	IFL
1332	Increased, serotonin (5-HT)	leads to	Increased, muscular waves in foot
1333	Increased, serotonin (5-HT)	leads to	Increase, cilia movement
1334	Increased, valve movement	leads to	Induced parturition
1335	Increase, cilia movement	leads to	Induced parturition
1336	Increased, serotonin (5-HT)	leads to	increased mantel display
1337	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	leads to	Increased, oocyte maturation
1338	Decompartmentalization	leads to	Mitochondrial impairment
1339	Direct mitochondrial inhibition	leads to	Mitochondrial impairment
1340	narcosis	leads to	Mitochondrial impairment
1341	Mitochondrial impairment	leads to	Apoptosis
1342	Mitochondrial impairment	leads to	Necrosis
1343	Increase, EcR agonism	leads to	Increase, E75b expression
1344	Increase, E75b expression	leads to	Increase, Ftz-f1 expression
1345	Increase, Ftz-f1 expression	leads to	Decrease, Circulating ETH
1346	Decrease, Circulating ETH	leads to	Decrease, Circulating CCAP
1347	Decrease, Circulating CCAP	leads to	Decrease, Ecdysis motoneuron bursts
1348	Decrease, Ecdysis motoneuron bursts	leads to	Decrease, Excitatory postsynaptic potential
1349	Decrease, Excitatory postsynaptic potential	leads to	Decrease, Abdominal muscle contraction
1350	dimerization, AHR/ARNT	leads to	Increase, COX-2 expression
1351	Increase, COX-2 expression	leads to	Altered, Cardiovascular development/function
1352	Altered, Cardiovascular development/function	leads to	Increase, Mortality
1353	Inactivation of PPARγ	leads to	Activation of TGF-β signaling
1354	Activation of TGF-β signaling	leads to	Differentiation of Myofibroblast
1355	Activation of TGF-β signaling	leads to	Expression of Collagen
1356	Differentiation of Myofibroblast	leads to	Production of α-smooth muscle actin
1357	Expression of Collagen	leads to	Collagen Deposition
1358	Production of α-smooth muscle actin	leads to	Lung fibrosis
1359	Collagen Deposition	leads to	Lung fibrosis
1360	Activation, NADPH Oxidase	leads to	ROS formation
1361	ROS formation	leads to	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK
1362	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK	leads to	Increased, DNA Damage-Repair
1363	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK	leads to	Damaging, Mitochondria
1364	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK	leads to	Activation, HIF-1
1365	Activation, HIF-1	leads to	Apoptosis
1366	Increased, DNA Damage-Repair	leads to	Apoptosis
1367	Damaging, Mitochondria	leads to	Apoptosis
1368	Apoptosis	leads to	Reproductive failure
1369	Activation, JAK/STAT pathway	leads to	Activation, TGF-beta pathway
1370	Activation, TGF-beta pathway	leads to	Reproductive failure
1371	Up Regulation, SREBF2	leads to	Up Regulation, Unsaturated fatty acid
1372	Up Regulation, Unsaturated fatty acid	leads to	Perturbation of cholesterol
1373	Down Regulation, GSS and GSTs gene	leads to	Glutathione synthesis
1374	Glutathione synthesis	leads to	Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene
1375	Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene	leads to	Perturbation of cholesterol
1376	Down Regulation, GSS and GSTs gene	leads to	Glutathione homeostasis
1377	Perturbation of cholesterol	leads to	Hepatotoxicity
1378	Glutathione homeostasis	leads to	Hepatotoxicity
1379	Peptide Oxidation	leads to	Activation, JNK
1380	Activation, JNK	leads to	Activation, FOXO
1381	Activation, FOXO	leads to	Inhibition, Wnt pathway
1382	Inhibition, Wnt pathway	leads to	Defect of Embryogenesis
1383	Defect of Embryogenesis	leads to	Reproductive failure
1384	Agonism, Androgen receptor	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1385	Agonism, Androgen receptor	leads to	Reduction, Vitellogenin synthesis in liver
1386	Reduction, Plasma 17beta-estradiol concentrations	leads to	Reduction, Plasma vitellogenin concentrations
1387	T4 in serum, Decreased	leads to	Hippocampal gene expression, Altered
1388	T4 in serum, Decreased	leads to	Hippocampal anatomy, Altered
1389	T4 in serum, Decreased	leads to	Hippocampal Physiology, Altered
1390	Increase, insulin	leads to	Activation, insulin receptor
1391	Activation, insulin receptor	leads to	Activation, mTORC2
1392	Activation, mTORC2	leads to	Activation, AKT
1393	Activation, mTORC2	leads to	Activation, mTORC1
1394	Activation, AKT	leads to	Activation, SREBP-1
1395	Activation, mTORC1	leads to	Activation, L-FABP
1396	Activation, mTORC1	leads to	Activation, HSD17B4
1397	Activation, SREBP-1	leads to	Activation, FXR
1398	Activation, AKT	leads to	Activation, mTORC1
1399	Activation, mTORC1	leads to	Activation, SREBP-1
1400	Activation, AKT	leads to	Activation, L-FABP
1401	Activation, L-FABP	leads to	Increase, cytosolic fatty acid
1402	demethylation, PPARg promoter	leads to	Activation, SREBP-1
1403	Activation, SREBP-1	leads to	Activation, SCD-1
1404	Activation, SCD-1	leads to	Increased, lipogenesis
1405	Increased, lipogenesis	leads to	Increase, cytosolic fatty acid
1406	Activation, NRF2	leads to	Activation, FXR
1407	Activation, FXR	leads to	Activation, SHP
1408	Activation, FXR	leads to	Activation, PPARα
1409	Activation, SHP	leads to	Activation, PPARα
1410	Activation, PPARα	leads to	Activation, HSD17B4
1411	Activation, HSD17B4	leads to	Inhibition, Mitochondrial fatty acid beta-oxidation
1412	Activation, SHP	leads to	Inhibition, LXR
1413	Inhibition, LXR	leads to	Inhibition, PPAR alpha
1414	Activation, SHP	leads to	Inhibition, LRH-1
1415	Activation, HSD17B4	leads to	Increase, Fatty acid β-oxidation
1416	Increase, Fatty acid β-oxidation	leads to	Inhibition, Steatosis
1417	Increase, Fatty acid β-oxidation	leads to	Decrease, cytosolic fatty acid
1418	Activation, PI3K	leads to	Activation, AKT
1419	Activation, PI3K	leads to	Activation, L-FABP
1420	Activation, PI3K	leads to	Activation, aPKC
1421	Activation, aPKC	leads to	Activation, SREBP-1
1422	Activation, FAS	leads to	Increased, lipogenesis
1423	Activation, L-FABP	leads to	demethylation, PPARg promoter
1424	demethylation, PPARg promoter	leads to	Activation, FAS
1425	Activation, LRH-1	leads to	Activation, FAS
1426	Decreased, serotonin transporter activity	leads to	Increased, intracellular sodium (Na+)
1427	Decreased, serotonin transporter activity	leads to	Increased, intracellular chloride (Cl-)
1428	Decreased, serotonin transporter activity	leads to	Decreased, extracellular Na+
1429	Decreased, serotonin transporter activity	leads to	Decreased, extracellular chloride (Cl-)
1430	Decreased, serotonin transporter activity	leads to	Increased, extracellular serotonin
1431	Decreased, serotonin transporter activity	leads to	Decreased, intracellular serotonin
1432	Decreased, intracellular serotonin	leads to	Decreased, packaged serotonin
1433	Decreased, packaged serotonin	leads to	Decreased, synaptic release
1434	Decreased, synaptic release	leads to	Decreased, extracellular serotonin
1435	Decreased, extracellular serotonin	leads to	Increased, 5-HT3
1436	Decreased, extracellular serotonin	leads to	Inactivated, 5-HTR
1437	Decreased, extracellular serotonin	leads to	Activation, 5-HT2A
1438	Activation, 5-HT2A	leads to	Activate, PLC
1439	Activate, PLC	leads to	Increase, inositol triphosphate
1440	Increase, inositol triphosphate	leads to	Increase, intracellular calcium
1441	Increase, intracellular calcium	leads to	Activate, calmodulin
1442	Activate, calmodulin	leads to	Increase, myosin light chain phosphorylation
1443	Increase, myosin light chain phosphorylation	leads to	Increase, vascular smooth muscle contraction
1444	Increase, vascular smooth muscle contraction	leads to	Increase, hypertension
1445	Increased, 5-HT3	leads to	Increased, seizure
1446	Inactivated, 5-HTR	leads to	Reduce expression, BDNF
1447	Reduce expression, BDNF	leads to	Decreased, neuroplasticity
1448	Decreased, neuroplasticity	leads to	Increased, agitation
1449	Decreased, neuroplasticity	leads to	Increased, depression
1450	Increase, cortisone	leads to	Activation, Glucocorticoid Receptor
1451	Activation, Glucocorticoid Receptor	leads to	Reduced, BDNF
1452	Activated, presynaptic neuron 1	leads to	Increased, glutamate
1453	Increased, glutamate	leads to	Activated, NMDA receptor
1454	Activated, NMDA receptor	leads to	Increased, intracellular sodium (Na+)
1455	Increased, intracellular sodium (Na+)	leads to	Activated, voltage-gated sodium channel
1456	Treat, carbamazepine	leads to	Inhibit, voltage-gated sodium channel
1457	Activated, voltage-gated sodium channel	leads to	Activated, membrane depolarization
1458	Activated, membrane depolarization	leads to	Increased, hippocampal hyperdepolarization
1459	Increased, hippocampal hyperdepolarization	leads to	Increase, seizure
1460	Increase, seizure	leads to	Increased, epilepsy
1461	Activate, presynaptic neuron 2	leads to	Increase, GABA
1462	Increase, GABA	leads to	Activate, GABA-A receptor
1463	Increased, RDX dose	leads to	Activate, GABA-A receptor
1464	Activate, GABA-A receptor	leads to	Increased, intracellular chloride (Cl-)
1465	Increased, intracellular chloride (Cl-)	leads to	Inactive, membrane depolarization
1466	Increase, ROS	leads to	Peptide Oxidation
1467	Peptide Oxidation	leads to	Increase, DNA Damage
1468	Increase, DNA Damage	leads to	Increase, Apoptosis
1469	Increase, Apoptosis	leads to	Decrease, Oogenesis
1470	Decrease, Oogenesis	leads to	Decrease, Ovulation
1471	Decrease, Ovulation	leads to	Decrease, Fertility
1472	Decrease, Fertility	leads to	Decrease, Population trajectory
1473	Increase, angiogenesis	leads to	Inhibit, gastric ulcer formation
1474	Increase, platelet aggregation	leads to	Inhibit, gastric ulcer formation
1475	Activate, mucosal defense	leads to	Inhibit, gastric ulcer formation
1476	Activate, leukocyte	leads to	Activated, gastric ulcer formation
1477	Increase, leukocyte adherence	leads to	Activate, leukocyte
1478	Activation, PTGS-2	leads to	Decrease, leukocyte adherence
1479	Activation, PTGS-2	leads to	Increase, angiogenesis
1480	Activation, PTGS-1	leads to	Increase, platelet aggregation
1481	Activation, PTGS-1	leads to	Increase, mucosal blood flow
1482	Activation, PTGS-1	leads to	Increase, mucous
1483	Activation, PTGS-1	leads to	Increase, bicarbonate
1484	Increase, bicarbonate	leads to	Activate, mucosal defense
1485	Increase, mucous	leads to	Activate, mucosal defense
1486	Increase, mucosal blood flow	leads to	Activate, mucosal defense
1487	Increase, ammonium (NH4+)	leads to	Decrease, surfactant
1488	Activate, phospholipase	leads to	Decrease, surfactant
1489	Increase, surfactant	leads to	Activate, mucosal defense
1491	Decreased, Population trajectory	leads to	Increased Mortality
1493	CYP7B activity, inhibition	leads to	7α-hydroxypregnenolone synthesis in the brain, decreased
1494	CYP7B activity, inhibition	leads to	Locomotor activity, decreased
1495	7α-hydroxypregnenolone synthesis in the brain, decreased	leads to	Locomotor activity, decreased
1496	7α-hydroxypregnenolone synthesis in the brain, decreased	leads to	Dopamine release in the brain, decreased
1497	Dopamine release in the brain, decreased	leads to	Locomotor activity, decreased
1498	7α-hydroxypregnenolone synthesis in the brain, decreased	leads to	Sexual behavior, decreased
1499	Sexual behavior, decreased	leads to	Decreased, Reproductive Success
1500	Locomotor activity, decreased	leads to	Decreased, Reproductive Success
1501	Decreased, Reproductive Success	leads to	Decreased, Population trajectory
1502	Dopamine release in the brain, decreased	leads to	Sexual behavior, decreased
1503	Inhibition, Na+/I- symporter (NIS)	leads to	Impairment, Learning and memory
1504	TH synthesis, Decreased	leads to	BDNF, Reduced
1505	TH synthesis, Decreased	leads to	GABAergic interneurons, Decreased
1506	TH synthesis, Decreased	leads to	Impairment, Learning and memory
1507	BDNF, Reduced	leads to	Impairment, Learning and memory
1508	Inhibition, Calcineurin Activity	leads to	Interference, nuclear localization of NFAT
1509	Reduction, NFAT/AP-1 complex formation	leads to	Suppression, IL-2 and IL-4 production
1510	Suppression, IL-2 and IL-4 production	leads to	Impairment, T-cell dependent antibody response
1511	Inactivated, 5-HTR	leads to	Reduced, BDNF
1512	Activation of Cyp2E1	leads to	Oxidative Stress
1513	Oxidative Stress	leads to	Hepatocytotoxicity
1514	Hepatocytotoxicity	leads to	Sustained proliferation
1515	Activation of Cyp2E1	leads to	Hepatocytotoxicity
1516	Oxidative Stress	leads to	Liver Cancer
1517	Hepatocytotoxicity	leads to	Liver Cancer
1518	Sustained proliferation	leads to	Liver Cancer
1519	Decreased, extracellular serotonin	leads to	Decreased, synaptic release
1520	Inhibit, serotonin transporter activity	leads to	Decreased, serotonin transporter activity
1521	Increased, extracellular serotonin	leads to	Decreased, extracellular serotonin
1522	Increased, glucocorticoid receptor activity	leads to	Reduced, BDNF
1523	Reduced, BDNF	leads to	Decreased, neuroplasticity
1524	Increased, serotonin transporter activity	leads to	Increased, intracellular serotonin
1525	Increased, intracellular serotonin	leads to	Increased, packaged serotonin
1526	Increased, packaged serotonin	leads to	Increased, synaptic release
1527	Increased, synaptic release	leads to	Increased, extracellular serotonin
1528	Increased, serotonin transporter activity	leads to	Decreased, extracellular serotonin
1529	Increased, extracellular serotonin	leads to	Decreased, 5-HT3
1530	Decreased, 5-HT3	leads to	Increased, seizure
1531	Increased, extracellular serotonin	leads to	Activation, 5-HT2A
1532	Reduced, PTGS1 function	leads to	Reduced, platelet aggregation
1533	Reduced, platelet aggregation	leads to	Activated, gastric ulcer formation
1534	Reduced, PTGS1 function	leads to	Decreased, mucosal blood flow
1535	Decreased, mucosal blood flow	leads to	Reduced, mucosal defense
1536	Reduced, mucosal defense	leads to	Activated, gastric ulcer formation
1537	Reduced, PTGS1 function	leads to	Decreased, mucous
1538	Decreased, mucous	leads to	Reduced, mucosal defense
1539	Reduced, PTGS1 function	leads to	Decreased, bicarbonate
1540	Decreased, bicarbonate	leads to	Reduced, mucosal defense
1541	Reduced, PTGS2 function	leads to	Decreased, angiogenesis
1542	Decreased, angiogenesis	leads to	Activated, gastric ulcer formation
1543	Reduced, PTGS2 function	leads to	Increased, leukocyte adherence
1544	Increased, leukocyte adherence	leads to	Increased, leukocyte activation
1545	Increased, leukocyte activation	leads to	Activated, gastric ulcer formation
1546	Helicobacter pylori infection	leads to	Increase, ammonium (NH4+)
1547	Decrease, surfactant	leads to	Reduced, mucosal defense
1548	Reduced, mucosal defense	leads to	Helicobacter pylori infection
1549	Increased, hippocampal hyperdepolarization	leads to	Increased, seizure
1550	Increased, seizure	leads to	Increased, epilepsy
1551	Reduced, presynaptic neuron 2 activity	leads to	Decreased, GABA
1552	Decreased, GABA	leads to	Reduced, GABA-A receptor activation
1553	Reduced, GABA-A receptor activation	leads to	Decreased, intracellular chloride
1554	Decreased, intracellular chloride	leads to	Activated, membrane depolarization
1555	Increased, RDX dose	leads to	Reduced, GABA-A receptor activation
1556	NFE2/Nrf2 repression	leads to	Reduced, FXR activity
1557	Reduced, FXR activity	leads to	Reduced, SHP activity
1558	Reduced, SHP activity	leads to	Activated, LXR
1559	Activated, LXR	leads to	Reduced, PPARalpha
1560	Reduced, PPARalpha	leads to	Reduced, HSD17B4 activity
1561	Reduced, HSD17B4 activity	leads to	Reduced, fatty acid beta oxidation
1562	Reduced, fatty acid beta oxidation	leads to	Increased, steatosis
1563	Mu Opioid Receptor Agonism	leads to	Release of G Proteins
1564	Release of G Proteins	leads to	Opening of GIRK channels
1565	Opening of GIRK channels	leads to	hyperpolarisation, neuron
1566	hyperpolarisation, neuron	leads to	Analgesia
1567	Altered, Cardiovascular development/function	leads to	Increase, Early Life Stage Mortality
1568	Release of G Proteins	leads to	Inhibition of Ca Channels
1569	Inhibition of Ca Channels	leads to	Inhibition of neurotransmitter release
1570	Inhibition of neurotransmitter release	leads to	Analgesia
1571	Serotonin 1A Receptor Agonism	leads to	Release of G Proteins
1572	hyperpolarisation, neuron	leads to	Anti-depressant Activity
1573	Inhibition of neurotransmitter release	leads to	Anti-depressant Activity
1574	SP (Substance P) release, Local increase of SP	leads to	Increased Airway Hyper-responsiveness,Cough, Dyspnea
1575	Excitation, Trigeminal nerve excitation	leads to	SP (Substance P) release, Local increase of SP
1576	TRPA1 activation, TRPA1 Receptor	leads to	Generation of novel epitopes , Antigen presentation
1577	SP (Substance P) release, Local increase of SP	leads to	Leukocyte infiltration
1578	Excitation, Trigeminal nerve excitation	leads to	Increased CGRP
1579	Increased CGRP	leads to	Increased Airway Hyper-responsiveness,Cough, Dyspnea
1580	Increased CGRP	leads to	Increase, hypertension
1581	Increase, hypertension	leads to	Respiratory irritability
1582	Excitation, Trigeminal nerve excitation	leads to	Irritation induced sneezing
1583	Excitation, Trigeminal nerve excitation	leads to	Increased NKA
1584	Increased NKA	leads to	Increased Airway Hyper-responsiveness,Cough, Dyspnea
1585	Increased NKA	leads to	Leukocyte infiltration
1586	Increased CGRP	leads to	Leukocyte infiltration
1587	Increased CGRP	leads to	Respiratory irritability
1588	Sensing of the stressor	leads to	Pro-inflammatory cytokines increased
1589	Pro-inflammatory cytokines increased	leads to	SAA production increased
1590	SAA production increased	leads to	HDL-SAA formation
1591	HDL-SAA formation	leads to	Systemic cholesterol increased
1592	Systemic cholesterol increased	leads to	Foam cell formation
1593	HDL-SAA formation	leads to	Foam cell formation
1594	Foam cell formation	leads to	Plaque progression
1595	Increase, ROS	leads to	Increase, DNA Damage
1596	Increase, Apoptosis	leads to	Increase, Follicular atresia
1597	Increase, Follicular atresia	leads to	Decrease, Oogenesis
1598	Increase, ROS	leads to	Increase, LPO
1599	Increase, LPO	leads to	Decrease, Coupling of OXPHOS
1600	Decrease, Coupling of OXPHOS	leads to	Decrease, Mitochondrial ATP production
1601	Decrease, Mitochondrial ATP production	leads to	Decrease, Oogenesis
1602	Increase, ROS production	leads to	Increase, DNA Damage
1603	Increase, ROS production	leads to	Increase, LPO
1606	Activation, LXR alpha	leads to	Increased, De Novo FA synthesis
1607	Increased, De Novo FA synthesis	leads to	Increased, Liver Steatosis
1608	demethylation, PPARg promoter	leads to	Activation of specific nuclear receptors, PPAR-gamma activation
1609	Activation of specific nuclear receptors, PPAR-gamma activation	leads to	increased adipogenesis
1610	activation of CEBPA	leads to	Activation of specific nuclear receptors, PPAR-gamma activation
1611	activation of CEBPA	leads to	increased adipogenesis
1612	increased adipogenesis	leads to	obesity
1613	chronic high fat diet	leads to	decreased dopamine
1614	decreased dopamine	leads to	decreased reward
1615	decreased reward	leads to	decreased DNA methylation of tyrosine hydroxylase
1616	decreased reward	leads to	decreased methylation of dopamine transporter promoter
1617	decreased reward	leads to	decreased dopamine
1618	decreased DNA methylation of tyrosine hydroxylase	leads to	obesity
1619	decreased methylation of dopamine transporter promoter	leads to	obesity
1620	decreased DNA methylation of tyrosine hydroxylase	leads to	decreased dopamine
1621	decreased methylation of dopamine transporter promoter	leads to	decreased dopamine
1622	Sustained inflammatory cytokine release	leads to	Increased, secretion of local growth factors
1623	Increase, ROS production	leads to	Increased, secretion of local growth factors
1624	Increased, secretion of local growth factors	leads to	Differentiation of fibroblasts
1625	Increased, secretion of local growth factors	leads to	EMT
1626	Differentiation of fibroblasts	leads to	Expression of Collagen
1627	EMT	leads to	Expression of Collagen
1628	Collagen Deposition	leads to	Accumulation, Collagen
1629	Accumulation, Collagen	leads to	Pulmonary fibrosis
1630	Cell damage sensing	leads to	Sustained inflammatory cytokine release
1631	Cell damage sensing	leads to	Increase, ROS production
1632	Cell damage sensing	leads to	Increased, secretion of local growth factors
1633	Sustained inflammatory cytokine release	leads to	Differentiation of fibroblasts
1634	Binding, topoisomerase II	leads to	DSB
1635	DSB	leads to	MLL translocation
1636	Thiol protein adducts	leads to	Inhibition of lysyl oxidase
1637	Inhibition of lysyl oxidase	leads to	Reduction of collagen crosslinking
1638	Reduction of collagen crosslinking	leads to	Weak collagen matrix
1639	Weak collagen matrix	leads to	Notochord malformation
1640	Notochord malformation	leads to	Reduced, Swimming performance
1641	Reduced, Swimming performance	leads to	Growth, reduction
1642	Reduced, Swimming performance	leads to	Decreased, survival
1643	Decrease, histaminergic neuron excitation	leads to	Impairment, Learning and memory
1644	Impairment, Learning and memory	leads to	Decreased, locomotion
1645	GR Agonist, Activation	leads to	Increased apoptosis, decreased Leydig Cells
1646	GR Agonist, Activation	leads to	Repressed expression of steroidogenic enzymes
1647	Increased apoptosis, decreased Leydig Cells	leads to	Reduction, Testosterone synthesis in Leydig cells
1648	Repressed expression of steroidogenic enzymes	leads to	Reduction, Testosterone synthesis in Leydig cells
1649	Reduction, testosterone level	leads to	Decreased sperm quantity or quality in the adult, Decreased fertility
1650	Decreased sperm quantity or quality in the adult, Decreased fertility	leads to	impaired, Fertility
1651	TGFbeta1 activation	leads to	TGFbeta pathway activation
1652	TGFbeta pathway activation	leads to	Differentiation of fibroblasts
1653	TGFbeta pathway activation	leads to	EMT
1654	Differentiation of fibroblasts	leads to	Accumulation, Collagen
1655	EMT	leads to	Accumulation, Collagen
1656	Activation, AhR	leads to	Up Regulation, SCD-1
1657	Up Regulation, SCD-1	leads to	Accumulation, Triglyceride
1658	Increased, FA Influx	leads to	Increased, Triglyceride formation
1659	demethylation, PPARg promoter	leads to	Increased, FA Influx
1660	Decreased, Ketogenesis	leads to	Accumulation, Fatty acid
1661	Activation, AKT2	leads to	Activation, SREBF1
1662	Activation, SREBF1	leads to	Increased, Liver Steatosis
1663	Increase, Uncoupling of photophosphorylation	leads to	Decrease, Chloroplast ATP production
1664	Decrease, Chloroplast ATP production	leads to	Decrease, Chlorophyll synthesis
1665	Decrease, Chlorophyll synthesis	leads to	Decrease, Light harvest capacity
1666	Decrease, Light harvest capacity	leads to	Decrease, Photosynthesis
1667	Decrease, Photosynthesis	leads to	Decrease, Glycolysis
1668	Decrease, Glycolysis	leads to	Decrease, OXPHOS
1669	Decrease, OXPHOS	leads to	Decrease, Mitochondrial ATP production
1670	Decrease, Mitochondrial ATP production	leads to	Decrease, Leaf cell mitosis
1671	Decrease, Leaf cell mitosis	leads to	Decrease, Leaf development
1672	Decrease, Leaf development	leads to	Increase, Growth inhibition
1673	Inhibition, mitochondrial DNA polymerase gamma (Pol gamma)	leads to	Depletion, mtDNA
1674	Depletion, mtDNA	leads to	Dysfunction, Mitochondria
1675	Dysfunction, Mitochondria	leads to	Increase, Cytotoxicity (renal tubular cell)
1676	Increase, Cytotoxicity (renal tubular cell)	leads to	Occurrence, Kidney toxicity
1677	Binding of substrate, endocytic receptor	leads to	Disturbance, Lysosomal function
1678	Disturbance, Lysosomal function	leads to	Disruption, Lysosome
1679	Disruption, Lysosome	leads to	Increase, Cytotoxicity (renal tubular cell)
1680	Alkylation, Protein	leads to	Dysfunction, Mitochondria
1681	Dysfunction, Mitochondria	leads to	Decrease, Mitochondrial ATP production
1682	Decrease, Mitochondrial ATP production	leads to	Increase, Cytotoxicity (renal tubular cell)
1683	Binding, SH/SeH proteins involved in protection against oxidative stress	leads to	N/A, Mitochondrial dysfunction 1
1684	N/A, Mitochondrial dysfunction 1	leads to	Oxidative Stress
1685	Oxidative Stress	leads to	Glutamate dyshomeostasis
1686	Glutamate dyshomeostasis	leads to	Cell injury/death
1687	Neuroinflammation	leads to	Cell injury/death
1688	Cell injury/death	leads to	Neuronal network function, Decreased
1689	Binding, SH/SeH proteins involved in protection against oxidative stress	leads to	Oxidative Stress
1690	Oxidative Stress	leads to	Cell injury/death
1691	Glutamate dyshomeostasis	leads to	Neuronal network function, Decreased
1692	Inhibition of fatty acid beta oxidation	leads to	Increase, cytosolic fatty acid
1693	Increase, cytosolic fatty acid	leads to	steatohepatitis
1694	Increase, cytosolic fatty acid	leads to	Increased, Liver Steatosis
1695	Increased, Liver Steatosis	leads to	Increased, Reactive oxygen species
1696	Increased, Reactive oxygen species	leads to	increased, oncotic necrosis
1697	increased, oncotic necrosis	leads to	steatohepatitis
1698	Peptide Oxidation	leads to	S-Glutathionylation, eNOS
1699	Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways	leads to	Activation, Dendritic Cells
1700	N/A, Covalent binding to protein, possibly lysine residue	leads to	Activation, Dendritic Cells
1701	Activation/Proliferation, T-cells	leads to	Increase, Allergic Respiratory Hypersensitivity Response
1702	Interaction with the lung cell membrane	leads to	Increased proinflammatory mediators
1703	Increased proinflammatory mediators	leads to	Recruitment of inflammatory cells
1704	Recruitment of inflammatory cells	leads to	Loss of alveolar capillary membrane integrity
1705	Loss of alveolar capillary membrane integrity	leads to	Activation of Th2 cells
1706	Activation of Th2 cells	leads to	Increased cellular proliferation and differentiation
1707	Increased cellular proliferation and differentiation	leads to	Increased extracellular matrix deposition
1708	Increased extracellular matrix deposition	leads to	Pulmonary fibrosis
1709	Histone deacetylase inhibition	leads to	Histone acetylation, increase
1710	Histone acetylation, increase	leads to	p21 (CDKN1A) expression, increase
1711	p21 (CDKN1A) expression, increase	leads to	Cell cycle, disrupted
1712	Cell cycle, disrupted	leads to	Apoptosis
1713	Apoptosis	leads to	Testicular atrophy
1714	Histone deacetylase inhibition	leads to	p21 (CDKN1A) expression, increase
1715	Histone deacetylase inhibition	leads to	Cell cycle, disrupted
1716	Histone deacetylase inhibition	leads to	Apoptosis
1717	Histone deacetylase inhibition	leads to	Testicular atrophy
1718	Cell injury/death	leads to	Tissue resident cell activation
1719	Increased pro-inflammatory mediators	leads to	Cell injury/death
1720	Activation of PPARγ	leads to	Increase, Inflammation
1721	Activation of TGF-β signaling	leads to	Increase, Inflammation
1722	Increase, Inflammation	leads to	Expression of Collagen
1723	Activation of TGF-β signaling	leads to	EMT
1724	Increase, Inflammation	leads to	EMT
1725	EMT	leads to	Lung fibrosis
1726	CYP2E1 Activation	leads to	Oxidative Stress in Brain
1727	Oxidative Stress in Brain	leads to	Lipid Peroxidation
1728	Lipid Peroxidation	leads to	Protein Adduct Formation
1729	Protein Adduct Formation	leads to	Unfolded Prortein Response
1730	Oxidative Stress in Brain	leads to	Unfolded Prortein Response
1731	Lipid Peroxidation	leads to	General Apoptosis
1732	Unfolded Prortein Response	leads to	General Apoptosis
1733	General Apoptosis	leads to	Neurodegeneration
1734	Spermatocyte depletion	leads to	Testicular atrophy
1735	Apoptosis	leads to	Spermatocyte depletion
1736	Increase, D1 protein antagonism	leads to	Decrease, PSII activity
1737	Decrease, PSII activity	leads to	Decrease, Photosynthesis
1738	Decrease, Glycolysis	leads to	Decrease, Mitochondrial ATP production
1739	Decrease, Mitochondrial ATP production	leads to	Decrease, Growth
1740	Decrease, PSII activity	leads to	Increase, ROS
1741	Increase, Apoptosis	leads to	Decrease, Growth
1742	Increase, CHS-1 inhibition	leads to	Decrease, Cuticular chitin content
1743	Decrease, Cuticular chitin content	leads to	Increase, Premature molting
1744	Increase, Premature molting	leads to	Increase, Mortality
1745	Increase, SUR binding	leads to	Increase, Cell membrane depolarization
1746	Increase, Cell membrane depolarization	leads to	Increase, Opening of voltage-dependent calcium channel
1747	Increase, Opening of voltage-dependent calcium channel	leads to	Decrease, Cuticular chitin content
1748	Decreased, PPARalpha transactivation of gene expression	leads to	Fatty Acid Beta Oxidation, Decreased
1749	Fatty Acid Beta Oxidation, Decreased	leads to	Decreased, Ketogenesis (production of ketone bodies)
1750	Decrease, Mitochondrial ATP production	leads to	Increase, Apoptosis
1751	Increase, Apoptosis	leads to	Increase, Mortality
1752	Decrease, Oogenesis	leads to	Decrease, Fecundity
1753	Decrease, Ovulation	leads to	Decrease, Fecundity
1754	Increase, ROS production	leads to	Decrease, Coupling of OXPHOS
1755	Blockade, L-Type Calcium Channels	leads to	Decrease, Calcium currents
1756	Decrease, Calcium currents	leads to	Decrease, Calcium binding to Troponin C
1757	Decrease, Calcium binding to Troponin C	leads to	Decrease, Cardiac contractility
1758	Decrease, Cardiac contractility	leads to	Decrease, Cardiac ejection fraction
1759	Decrease, Cardiac ejection fraction	leads to	Heart failure
1760	Decrease, Calcium currents	leads to	Disruption, Intracellular calcium mobilization
1761	Disruption, Intracellular calcium mobilization	leads to	Disruption, Sarcomere assembly
1762	Disruption, Sarcomere assembly	leads to	Decrease, Cardiac contractility
1763	Tissue resident cell activation	leads to	Increased pro-inflammatory mediators
1764	Increased pro-inflammatory mediators	leads to	Activation, Stellate cells
1765	Binding, SH/SeH proteins involved in protection against oxidative stress	leads to	Protection against oxidative stress, decreased
1766	Protection against oxidative stress, decreased	leads to	Oxidative Stress
1767	Inhibition, Aromatase	leads to	Altered regulation, Alpha hemoglobin
1768	TH synthesis, Decreased	leads to	Reduction, Plasma 17beta-estradiol concentrations
1769	Reduction, Plasma vitellogenin concentrations	leads to	Reduction, Cumulative fecundity and spawning
1770	Respiratory irritability	leads to	Increased Airway Hyper-responsiveness,Cough, Dyspnea
1771	Increased Airway Hyper-responsiveness,Cough, Dyspnea	leads to	Respiratory irritability
1772	SP (Substance P) release, Local increase of SP	leads to	Respiratory irritability
1773	Increased NKA	leads to	Respiratory irritability
1774	Irritation induced sneezing	leads to	Increased Airway Hyper-responsiveness,Cough, Dyspnea
1775	endocytosis	leads to	Disruption, Lysosome
1776	Cell injury/death	leads to	Increased pro-inflammatory mediators
1777	Increased pro-inflammatory mediators	leads to	Leukocyte recruitment/activation
1778	Leukocyte recruitment/activation	leads to	Activation, Stellate cells
1779	EMT	leads to	Collagen Deposition
1780	Mitochondrial Complex I inhibition	leads to	Decrease in mitochondrial oxidative phosphorylation
1781	Increase, Mitochondrial complex III antagonism	leads to	Decrease in mitochondrial oxidative phosphorylation
1782	Mitochondrial Complex IV inhibition	leads to	Decrease in mitochondrial oxidative phosphorylation
1783	Mitochondrial Complex V inhibition	leads to	Decrease in mitochondrial oxidative phosphorylation
1784	Increase, Mitochondrial complex III antagonism	leads to	Increased reactive oxygen species (in the mitochondria)
1785	Mitochondrial Complex IV inhibition	leads to	Increased reactive oxygen species (in the mitochondria)
1786	Mitochondrial Complex V inhibition	leads to	Increased reactive oxygen species (in the mitochondria)
1787	Decrease in mitochondrial oxidative phosphorylation	leads to	Mitochondrial Injury
1788	Increased reactive oxygen species (in the mitochondria)	leads to	Mitochondrial Injury
1789	Necrotic Tissue	leads to	Liver Injury
1790	Mitochondrial Complex I inhibition	leads to	Increased reactive oxygen species (in the mitochondria)
1791	Ionizing Energy	leads to	DNA DNA double strand breaks
1792	DNA DNA double strand breaks	leads to	DNA repair
1793	DNA repair	leads to	Increase mutations
1794	DNA repair	leads to	Increase chromosomal aberrations
1795	Increase mutations	leads to	Increase cell proliferation
1796	Increase chromosomal aberrations	leads to	Increase cell proliferation
1797	Increase cell proliferation	leads to	Increase, lung cancer
1798	Ionizing Energy	leads to	Increase mutations
1799	Ionizing Energy	leads to	Increase chromosomal aberrations
1800	Increase mutations	leads to	Increase, lung cancer
1801	Increase chromosomal aberrations	leads to	Increase, lung cancer
1802	Histone deacetylase inhibition	leads to	Reduced neural crest cell migration
1803	Reduced neural crest cell migration	leads to	Reduced collagen production
1804	Reduced collagen production	leads to	Smaller and morphologically distorted facial cartilage structures
1805	Histone deacetylase inhibition	leads to	Reduced collagen production
1806	Histone acetylation, increase	leads to	Altered, Gene Expression
1807	Altered, Gene Expression	leads to	Altered differentiation
1808	Altered differentiation	leads to	Neural tube defects
1809	Inhibition, NADH-ubiquinone oxidoreductase (complex I)	leads to	Decrease, OXPHOS
1810	Decrease, OXPHOS	leads to	Decreased Na/K ATPase activity
1811	Decreased Na/K ATPase activity	leads to	Decreased proximal tubular vectorial transport
1812	Decreased proximal tubular vectorial transport	leads to	Chemical induced Fanconi syndrome
1813	Blocking of IL-1R	leads to	Impaired IL-1 signaling
1814	Decreased IL-1 production	leads to	Impaired IL-1 signaling
1815	Impaired IL-1 signaling	leads to	Suppressed AP-1
1816	Impaired IL-1 signaling	leads to	Suppressed NF-kB
1817	Suppressed AP-1	leads to	Suppressed DC activation
1818	Suppressed NF-kB	leads to	Suppressed DC activation
1819	Suppressed DC activation	leads to	Impaired antigen presentation
1820	Impaired antigen presentation	leads to	Impaired T cell activation
1821	Impaired T cell activation	leads to	Suppression, Suppression of T-cell dependent antibody response (TDAR)
1822	Impaired T cell activation	leads to	Increase, Increased susceptibility to infection
1823	Suppression, Suppression of T-cell dependent antibody response (TDAR)	leads to	Increase, Increased susceptibility to infection
1824	Decreased IL-1 production	leads to	Suppressed MyD88
1825	Impaired IL-1 signaling	leads to	Suppressed MyD88
1826	Suppressed MyD88	leads to	Increase, Increased susceptibility to infection
1827	Inhibition, IKK complex	leads to	Inhibition, Nuclear factor kappa B (NF-kB)
1828	Inhibition, Nuclear factor kappa B (NF-kB)	leads to	Activation, Caspase 8 pathway
1829	Activation, Caspase 8 pathway	leads to	Cell injury/death
1830	Cell injury/death	leads to	Necrotic Tissue
1831	Cell injury/death	leads to	Activation, Tissue resident cells (Kuppfer cells)
1832	Activation, Tissue resident cells (Kuppfer cells)	leads to	Increase, proinflammatory mediators (TNFalpha)
1833	Binding of MSAs to microtubules	leads to	Disturbance in microtubule dynamic instability
1834	Disturbance in microtubule dynamic instability	leads to	Impaired axonial transport
1835	Impaired axonial transport	leads to	Sensory axonal peripheral neuropathy
1836	Interaction of α-diketones with arginine residues	leads to	Proteasomal dysfunction
1837	Proteasomal dysfunction	leads to	Airway epithelial injury
1838	Airway epithelial injury	leads to	Increase, Inflammation
1839	Increase, Inflammation	leads to	Fibroproliferative airway lesions
1840	EMT	leads to	Fibroproliferative airway lesions
1841	Fibroproliferative airway lesions	leads to	Bronchiolitis obliterans
1842	Distribution of chemicals	leads to	Absorption of photon energy
1843	Absorption of photon energy	leads to	ROS generation
1844	Absorption of photon energy	leads to	Radical generation
1845	ROS generation	leads to	Oxidation of membrane lipids
1846	ROS generation	leads to	Oxidation/denatuation of membrane proteins
1847	ROS generation	leads to	Oxidation of DNA
1848	Radical generation	leads to	DNA photo-adducts
1849	Radical generation	leads to	Protein photo-adducts
1850	Oxidation of membrane lipids	leads to	Inflammatory events
1851	Oxidation/denatuation of membrane proteins	leads to	Inflammatory events
1852	Oxidation of DNA	leads to	Inflammatory events
1853	DNA photo-adducts	leads to	Inflammatory events
1854	Protein photo-adducts	leads to	Inflammatory events
1855	Inflammatory events	leads to	Eczematous eruption
1856	Eczematous eruption	leads to	Scaling, Lichenification
1857	ACh Synaptic Accumulation	leads to	Activation, Muscarinic Acetylcholine Receptors
1858	Activation, Muscarinic Acetylcholine Receptors	leads to	Increased, glutamate
1859	Increased, glutamate	leads to	Overactivation, NMDARs
1860	Increased, Intracellular Calcium overload	leads to	Occurrence, Epileptic seizure
1861	Occurrence, Epileptic seizure	leads to	Increased, glutamate
1862	Increased, Intracellular Calcium overload	leads to	Cell injury/death
1863	Cell injury/death	leads to	Neurodegeneration
1864	Inhibition of N-linked glycosylation	leads to	Accumulation, misfolded proteins
1865	Accumulation, misfolded proteins	leads to	Unfolded Prortein Response
1866	Unfolded Prortein Response	leads to	Apoptosis
1867	Apoptosis	leads to	Activation, hepatic stellate cells
1868	Activation, hepatic stellate cells	leads to	Liver Injury
1869	Apoptosis	leads to	Liver Injury
1870	Suppressed MyD88	leads to	Inhibition, Nuclear factor kappa B (NF-kB)
1871	Inhibition, Nuclear factor kappa B (NF-kB)	leads to	Increase, Increased susceptibility to infection
1872	Increase, Mitochondrial complex III antagonism	leads to	Decrease, OXPHOS
1873	Decrease, Mitochondrial ATP production	leads to	Increase, Necrosis
1874	Increase, Necrosis	leads to	Increase, Mortality
1875	Increase, Mitochondrial complex III antagonism	leads to	Increase, ROS
1876	Increase, ROS	leads to	Increase,Oxidative DNA damage
1877	Increase,Oxidative DNA damage	leads to	Increase, Apoptosis
1878	Inhibition of Cyp17A1 activity	leads to	Reduction, DHEA
1879	Inhibition of Cyp17A1 activity	leads to	Reduction, androstenedione
1880	5α-reductase, inhibition	leads to	Decrease, DHT level
1881	Decrease, DHT level	leads to	Reduction, Plasma 17beta-estradiol concentrations
1882	Reduction, Plasma vitellogenin concentrations	leads to	Reduction, egg production and spawning
1883	Increase, DNMT inhibition	leads to	Increase, DNA hypomethylation
1884	Increase, DNA hypomethylation	leads to	Increase, Gene expression
1885	Increase, Gene expression	leads to	Decrease, Fecundity
1886	Decrease, Fecundity	leads to	Decrease, Population trajectory
1887	Increase, DNA hypomethylation	leads to	Decrease, Transgenerational DNA methylation
1888	Decrease, Transgenerational DNA methylation	leads to	Increase, Gene expression
1889	Activation, Muscarinic Acetylcholine Receptors	leads to	Occurrence, Focal Seizure
1890	Occurrence, Focal Seizure	leads to	Increased, glutamate
1891	tyrosinase	leads to	Reduction of L-Dopaquinone
1892	Reduction of L-Dopaquinone	leads to	Reduction in melanin level
1893	Reduction in melanin level	leads to	Reduction of melanosome level
1894	Reduction of melanosome level	leads to	Reduction fo Pigmentation pattern
1895	Reduction fo Pigmentation pattern	leads to	Decrease, Population trajectory
1896	Increase, Mutations	leads to	Increase, Cell Proliferation (Epithelial Cells)
1897	Increase, DNA Damage	leads to	Increase, Mutations
1898	Increase, DNA Damage	leads to	Tissue resident cell activation
1899	Increase, DNA Damage	leads to	Increase mutations
1900	Increase mutations	leads to	Increase, Cell Proliferation (Epithelial Cells)
1901	Leukocyte recruitment/activation	leads to	Increase, Cell Proliferation (Epithelial Cells)
1902	Increased pro-inflammatory mediators	leads to	N/A, Breast Cancer
1903	Increased pro-inflammatory mediators	leads to	Increase in RONS
1904	Increase in RONS	leads to	Increase, DNA Damage
1905	Leukocyte recruitment/activation	leads to	Increase in RONS
1906	Increase in RONS	leads to	Tissue resident cell activation
1907	Increase, Cell Proliferation (Epithelial Cells)	leads to	Increase, Mutations
1908	Increased pro-inflammatory mediators	leads to	Increase, Cell Proliferation (Epithelial Cells)
1909	Increase, Oxidative DNA damage	leads to	N/A, Inadequate DNA repair
1910	N/A, Inadequate DNA repair	leads to	Increase, DNA strand breaks
1911	Increase, DNA strand breaks	leads to	N/A, Inadequate DNA repair
1912	N/A, Inadequate DNA repair	leads to	Increase, Chromosomal aberrations
1913	Increase, Oxidative DNA damage	leads to	Increase, DNA strand breaks
1914	Increase, Oxidative DNA damage	leads to	Increase, Mutations
1915	Retinaldehyde dehydrogenase	leads to	retinoic acid
1916	retinoic acid	leads to	plasma retionic acid
1917	plasma retionic acid	leads to	Optical elements of the eye
1918	Optical elements of the eye	leads to	Visual impairment
1919	Visual impairment	leads to	Decline, Population
1920	Impaired IL-1 signaling	leads to	Inhibition, Nuclear factor kappa B (NF-kB)
1921	Inhibition, Nuclear factor kappa B (NF-kB)	leads to	Impaired T cell activation
1922	Impaired T cell activation	leads to	Impaired Ab production
1923	Impaired Ab production	leads to	Increase, Increased susceptibility to infection
1924	Wnt ligand stimulation	leads to	Frizzled activation
1925	Frizzled activation	leads to	GSK3beta inactivation
1926	GSK3beta inactivation	leads to	β-catenin activation
1927	β-catenin activation	leads to	Snail, Zeb, Twist activation
1928	Snail, Zeb, Twist activation	leads to	Epithelial-mesenchymal transition
1929	Epithelial-mesenchymal transition	leads to	Resistant gastric cancer
1930	Increase, SAM depletion	leads to	Increase, DNA hypomethylation
1931	Increase, DNA strand breaks	leads to	Increase, Mutations
1932	Reduction, DHEA	leads to	Decrease, testosterone level
1933	Reduction, androstenedione	leads to	Decrease, testosterone level
1934	Decrease, testosterone level	leads to	Decrease, DHT level
1935	Decrease, DHT level	leads to	Decrease, AR activation
1936	Decrease, testosterone level	leads to	Decrease, AR activation
1937	Decrease, AR activation	leads to	Impaired inguinoscrotal phase
1938	Impaired inguinoscrotal phase	leads to	Malformation, cryptorchidism
1939	Increase, DNA strand breaks	leads to	Increase, Chromosomal aberrations
1940	Inhibition, NADH-ubiquinone oxidoreductase (complex I)	leads to	Decrease in mitochondrial oxidative phosphorylation
1941	Mitochondrial Injury	leads to	Increased reactive oxygen species (in the mitochondria)
1942	Mitochondrial Injury	leads to	Impaired, Proteostasis
1943	Impaired, Proteostasis	leads to	Cell injury/death
1944	Binding of inhibitor, mitochondrial complex III	leads to	Increase, Mitochondrial complex III antagonism
1945	Binding of inhibitor, mitochondrial complex IV	leads to	Mitochondrial Complex IV inhibition
1946	Binding of inhibitor, mitochondrial complex V	leads to	Mitochondrial Complex V inhibition
1947	TR Antagnoism	leads to	Hippocampal gene expression, Altered
1948	TR Antagnoism	leads to	Cognitive Function, Decreased
1949	CBS inhibition	leads to	Homocysteine increases
1950	MTHFR inhibition	leads to	Homocysteine increases
1951	Methionine synthase	leads to	Homocysteine increases
1952	betaine-homocysteine methyltransferase inhibition	leads to	Homocysteine increases
1953	Homocysteine increases	leads to	plasma homocysteine increases
1954	plasma homocysteine increases	leads to	brain Homocysteine level increases
1955	brain Homocysteine level increases	leads to	Neuronal dysfunctions induction
1956	Decrease in mitochondrial oxidative phosphorylation	leads to	N/A, Mitochondrial dysfunction 1
1957	Increased reactive oxygen species (in the mitochondria)	leads to	N/A, Mitochondrial dysfunction 1
1958	N/A, Mitochondrial dysfunction 1	leads to	Increased reactive oxygen species (in the mitochondria)
1959	Homocysteine increases	leads to	Plasma HCY level
1960	Plasma HCY level	leads to	dysfunction of microcirculation
1961	dysfunction of microcirculation	leads to	anterior-posterior axis development
1962	Frustrated phagoytosis	leads to	Release, Cytokine
1963	Release, Cytokine	leads to	Recruitment of inflammatory cells
1964	Recruitment of inflammatory cells	leads to	Increased, Reactive oxygen species
1965	Increased, Reactive oxygen species	leads to	Increased, DNA damage and mutation
1966	Increased, DNA damage and mutation	leads to	Increase, Cell Proliferation
1967	Increase, Cell Proliferation	leads to	Lung cancer
1968	Substance - LS interaction	leads to	Inhibition of LS function.
1969	Inhibition of LS function.	leads to	Alveolar collapse
1970	Alveolar collapse	leads to	Alveolar reopening
1971	Alveolar reopening	leads to	Loss of barrier function
1972	Loss of barrier function	leads to	Blood extravasation into the lungs
1973	Blood extravasation into the lungs	leads to	Acute inhalation toxicity
1974	Alveolar collapse	leads to	Reduced lung volume
1975	Reduced lung volume	leads to	Impaired oxygenation of the blood
1976	Impaired oxygenation of the blood	leads to	Acute inhalation toxicity
1977	Energy Deposition	leads to	Increase, DNA strand breaks
1978	Increase, Mutations	leads to	Increase, Cell Proliferation
1979	Increase, Chromosomal aberrations	leads to	Increase, Cell Proliferation
1980	Increase, Cell Proliferation	leads to	Increase, lung cancer
1981	Energy Deposition	leads to	Increase, Mutations
1982	Energy Deposition	leads to	Increase, Chromosomal aberrations
1983	Energy Deposition	leads to	Increase, lung cancer
1984	Increase, Mutations	leads to	Increase, lung cancer
1985	Increase, Chromosomal aberrations	leads to	Increase, lung cancer
1986	Antagonism,LH receptor	leads to	Reduction, Progesterone synthesis
1987	Reduction, Progesterone synthesis	leads to	Reduction, Plasma progesterone concentration
1988	Reduction, Plasma progesterone concentration	leads to	Reduction, progesterone uptake, decresed maturation
1989	Reduction, progesterone uptake, decresed maturation	leads to	Impaired ovulation
1990	Impaired ovulation	leads to	Decrease of egg production and cummulative fecundity
1991	Decrease of egg production and cummulative fecundity	leads to	Decline, Population trajectory
1992	Activation, AhR	leads to	Increase, DNMT expression
1993	Increase, DNMT expression	leads to	Increase, hypermethylation of the promotor region of GnRHR
1994	Increase, hypermethylation of the promotor region of GnRHR	leads to	Decease, expression of GnRHR
1995	Decease, expression of GnRHR	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1996	dimerization, AHR/ARNT	leads to	Increase, DNMT expression
1997	Histone acetylation, increase	leads to	Cell cycle, disrupted
1998	Occurrence, Focal Seizure	leads to	Overactivation, NMDARs
1999	Occurrence, Epileptic seizure	leads to	Overactivation, NMDARs
2000	Impaired IL-1R1 signaling	leads to	Suppression of T cell activation
2001	Suppression of T cell activation	leads to	Inhibition, Nuclear factor kappa B (NF-kB)
2002	Impaired IL-1R1 signaling	leads to	Inhibition, Nuclear factor kappa B (NF-kB)
2003	Inhibition, Nuclear factor kappa B (NF-kB)	leads to	Suppression of T cell activation
2004	Suppression of T cell activation	leads to	Increase, Increased susceptibility to infection
2005	Increased Cholinergic Signaling	leads to	Cardiovascular dysregulation
2006	Cardiovascular dysregulation	leads to	Respiratory distress/arrest
2007	AchE Inhibition	leads to	Cardiovascular dysregulation
2008	Oxidative Stress	leads to	Wnt ligand stimulation
2009	Increased, Reactive oxygen species	leads to	Oxidative Stress
2010	Histone deacetylase inhibition	leads to	Spermatocyte depletion
2011	Increased Cholinergic Signaling	leads to	Impaired coordination and movement
2012	Impaired coordination and movement	leads to	Increased Mortality
2013	Increased Mortality	leads to	Decrease, Population trajectory
2014	AchE Inhibition	leads to	Impaired coordination and movement
2015	Impaired coordination and movement	leads to	Decrease, Population trajectory
2016	AchE Inhibition	leads to	Decrease, Population trajectory
2017	Stimulation of TLR7/8	leads to	Increase of IL-23
2018	Increase of IL-23	leads to	Th17 cell migration and inflammation induction
2019	Th17 cell migration and inflammation induction	leads to	Skin disease
2020	Binding to estrogen receptor (ER)-α	leads to	Induction of GATA3 expression
2021	Induction of GATA3 expression	leads to	Increase of Th2 cells producing IL-4
2022	Increase of Th2 cells producing IL-4	leads to	Increase of autoantibody production
2023	Increase of autoantibody production	leads to	Exacerbation of SLE
2024	Inhibition of JAK3	leads to	STAT5 inhibition
2025	STAT5 inhibition	leads to	Suppression of STAT5 binding
2026	Suppression of STAT5 binding	leads to	Suppression of IL-4 production
2027	Suppression of IL-4 production	leads to	Impairment, TDAR
2028	Inhibition, trypsin	leads to	Increased monitor peptide
2029	Increased monitor peptide	leads to	Increased blood CCK level
2030	Increased blood CCK level	leads to	Increased acinar cell exocrine secretion
2031	Increased acinar cell exocrine secretion	leads to	Acinar cell proliferation
2032	Acinar cell proliferation	leads to	Acinar cell tumors
2033	Increased, Reactive oxygen species	leads to	β-catenin activation
2034	test	leads to	Unknown, MIE
2035	Unknown, MIE	leads to	Unknown,
2036	Unknown, MIE	leads to	N/A, Unknown
2037	test	leads to	N/A, Unknown
2038	T4 in serum, Decreased	leads to	Decreased, Triiodothyronine (T3) in serum
2039	Activation, Glucocorticoid Receptor	leads to	Decreased, Mitochondrial Fatty Acid Beta Oxidation
2040	Decreased, Mitochondrial Fatty Acid Beta Oxidation	leads to	Increased, Liver Steatosis
2041	Activation, Glucocorticoid Receptor	leads to	Decreased, PPAR-alpha activation
2042	Decreased, PPAR-alpha activation	leads to	Increased, Liver Steatosis
2052	Increased viral entry and gene expression	leads to	Increased proinflammatory mediators
2053	Increased proinflammatory mediators	leads to	Pro-inflammatory cytokines increased
2056	ACE2 binding to viral S-protein	leads to	Increased viral entry and gene expression
2061	Increased proinflammatory mediators	leads to	Increased inflammatory immune responses
2062	Increased inflammatory immune responses	leads to	Increase, the risk of acute respiratory failure
2064	Increase, the risk of acute respiratory failure	leads to	Decreased mortality
2065	ACE2 inhibition	leads to	Increases AngII
2066	Increases AngII	leads to	Increase plasma Ang II
2067	Increase plasma Ang II	leads to	Increase,collagen synthesis
2068	Increase,collagen synthesis	leads to	Induction lung fibrosis
2069	Chronic ROS	leads to	Sustained tissue damage / macrophage activation/ porcupine-induced Wnt secretion
2070	Sustained tissue damage / macrophage activation/ porcupine-induced Wnt secretion	leads to	Proliferation/ beta-catenin activation
2071	Proliferation/ beta-catenin activation	leads to	Epithelial-mesenchymal transition
2072	Decreased, cholesterol	leads to	Decreased, 11KT
2073	Activation, PPARα	leads to	Decreased, cholesterol
2074	Increase, DNA strand breaks	leads to	Increase, Apoptosis
2075	Increase, Apoptosis	leads to	Reduce, Sperm count
2076	Decreased, 11KT	leads to	Impaired, Spermatogenesis
2077	Activation, Glucocorticoid Receptor	leads to	Increase, Cripto-1 expression
2078	Increase, Cripto-1 expression	leads to	Inhibition, Activin signaling
2079	Inhibition, Activin signaling	leads to	Inhibition, Fin regeneration
2080	Inhibition, Fin regeneration	leads to	Reduced, Swimming performance
2081	Reduced, Swimming performance	leads to	Decrease, Population trajectory
2082	Increase, Cripto-1 expression	leads to	Inhibition, Fin regeneration
2083	Mitochondrial impairment	leads to	cell injury
2084	cell injury	leads to	Increase, Regenerative cell proliferation (urothelial cells)
2085	Increase, Hyperplasia (urothelial)	leads to	carcinogenicity
2087	Increase, Formation of DNA photoproducts	leads to	Increase, DNA DSB
2088	Increase, DNA DSB	leads to	Increase, Apoptosis
2089	Increase, ROS production	leads to	Increase, Protein oxidation
2090	Increase, Protein oxidation	leads to	Increase, Abnormal osmoregulation
2091	Increase, Abnormal osmoregulation	leads to	Increase, Body fluid overload
2092	Increase, Body fluid overload	leads to	Increase, Mortality
2093	Increase, ROS production	leads to	Decrease, MMP
2094	Decrease, MMP	leads to	Decrease, OXPHOS
2095	Decrease, OXPHOS	leads to	Decrease, ATP pool
2096	Decrease, ATP pool	leads to	Increase, Mortality
2097	Increase, LPO	leads to	Decrease, Neutral lipids
2098	Decrease, Neutral lipids	leads to	Decrease, ATP pool
2099	Increase, ROS production	leads to	Increase,Oxidative DNA damage
2100	Increase,Oxidative DNA damage	leads to	Increase, DNA DSB
2101	Increase, DNMT inhibition	leads to	Decrease, Global DNA methylation
2102	Decrease, Global DNA methylation	leads to	Increase, Casp transcription
2103	Increase, Casp transcription	leads to	Increase, Oocyte apoptosis
2104	Increase, Oocyte apoptosis	leads to	Decrease, Oogenesis
2105	Increase, Casp transcription	leads to	Increase, Ovarian somatic cell apoptosis
2106	Increase, Ovarian somatic cell apoptosis	leads to	Increase, Ovarian follicle breakdown
2107	Increase, Ovarian follicle breakdown	leads to	Decrease, Oogenesis
2108	Increase, DNMT inhibition	leads to	Increase, DNA DSB
2109	Increase, DNA DSB	leads to	Increase, Casp transcription
2110	Decrease, Global DNA methylation	leads to	Decrease, Heritable DNA methylation (F3)
2111	Decrease, Heritable DNA methylation (F3)	leads to	Increase, Casp transcription (F3)
2112	Increase, Casp transcription (F3)	leads to	Increase, Oocyte apoptosis (F3)
2113	Increase, Oocyte apoptosis (F3)	leads to	Decrease, Oogenesis (F3)
2114	Decrease, Oogenesis (F3)	leads to	Decrease, Fecundity (F3)
2115	Decrease, Fecundity (F3)	leads to	Decrease, Population trajectory
2116	Increase, Casp transcription (F3)	leads to	Increase, Ovarian somatic cell apoptosis (F3)
2117	Increase, Ovarian somatic cell apoptosis (F3)	leads to	Increase, Ovarian follicle breakdown (F3)
2118	Increase, Ovarian follicle breakdown (F3)	leads to	Decrease, Oogenesis (F3)
2119	Increase, Mitochondrial ATP synthase antagonism	leads to	Decrease, OXPHOS
2120	Decrease, ATP pool	leads to	Increase, Oocyte apoptosis
2121	Decrease, ATP pool	leads to	Increase, Necrosis
2122	Increase, Necrosis	leads to	Increase, Ovarian follicle breakdown
2123	Antagonism, Androgen receptor	leads to	short male AGD
2124	Decrease, AR activation	leads to	Altered, Transcription of genes by AR
2125	Reduction, Testosterone synthesis in Leydig cells	leads to	reduction, testosterone levels
2126	reduction, testosterone levels	leads to	Decrease, DHT level
2127	Altered, Transcription of genes by AR	leads to	short male AGD
2128	Decrease, AR activation	leads to	decrease, transcription of genes by AR
2129	decrease, transcription of genes by AR	leads to	short male AGD
2130	Antagonism, Androgen receptor	leads to	Decrease, AR activation
2131	reduction, testosterone levels	leads to	Decrease, AR activation
2132	Altered, Transcription of genes by AR	leads to	nipple retention (NR) male
2133	Antagonism, Androgen receptor	leads to	nipple retention (NR) male
2134	Activation, PPARα	leads to	Decreased, 11KT
2135	Increase, the risk of acute respiratory failure	leads to	Increased Mortality
2136	ACE2 agonism	leads to	Increase plasma Ang II
2137	ACE2 agonism	leads to	Increases AngII
2138	Increase plasma Ang II	leads to	Accumulation, Collagen
2139	Accumulation, Collagen	leads to	Lung fibrosis
2140	Increased, Intracellular Calcium overload	leads to	Status epilepticus
2141	Status epilepticus	leads to	Overactivation, NMDARs
2142	Reduction, Cumulative fecundity and spawning	leads to	Decline, Population
2143	Visual impairment	leads to	Decrease, Population trajectory
2144	Inhibition, Aromatase	leads to	Reduction, E2 Synthesis by the undifferentiated gonad
2145	Reduction, E2 Synthesis by the undifferentiated gonad	leads to	Increased, Differentiation to Testis
2146	Increased, Differentiation to Testis	leads to	Increased, Male Biased Sex Ratio
2147	Increased, Male Biased Sex Ratio	leads to	Decrease, Population trajectory
2148	TLR4 activation	leads to	Activation, JNK
2149	Activation, JNK	leads to	AP-1 activation
2150	Activation, JNK	leads to	Pin-1 activation
2151	Pin-1 activation	leads to	TGFbeta expression
2152	TGFbeta expression	leads to	Activation, TGF-beta pathway
2153	Activation, TGF-beta pathway	leads to	EMT
2154	EMT	leads to	Pulmonary fibrosis
2155	TLR4 activation	leads to	Activation, TGF-beta pathway
2156	Inactivation of PPARγ	leads to	Activation, TGF-beta pathway
2157	AP-1 activation	leads to	TGFbeta expression
2158	11β-hydroxylase inhibition	leads to	Decreased, 11KT
2161	Decreased size and sperm volume	leads to	impaired, Fertility
2162	Inhibition of 11β-HSD	leads to	Decreased, 11KT
2164	Impaired, Spermatogenesis	leads to	Decrease, Fertility
2165	Decreased, 11KT	leads to	Decrease, Fertility
2166	Decreased, 11KT	leads to	Decreased size and sperm volume
2167	Inhibition, Aromatase	leads to	Increased, Differentiation to Testis
2168	T4 in serum, Decreased	leads to	Altered, Amphibian metamorphosis
2169	Decrease, Growth	leads to	Decrease, Population trajectory
2170	Increase, Chitinase inhibition	leads to	Decrease, Digestion of old cuticle
2171	Decrease, Digestion of old cuticle	leads to	Increase, Premature molting
2172	Increase, Chitobiase inhibition	leads to	Decrease, Digestion of old cuticle
2173	Alveolar reopening	leads to	Loss of alveolar capillary membrane integrity
2174	Loss of alveolar capillary membrane integrity	leads to	Blood extravasation into the lungs
2175	Decrease, Coupling of OXPHOS	leads to	Decrease, ATP synthase activity
2176	Decrease, ATP synthase activity	leads to	Decrease, ATP pool
2177	Increase, Necrosis	leads to	Increase, Tissue/organ damage
2178	Increase, Tissue/organ damage	leads to	Decrease, Growth
2179	Decrease, ATP pool	leads to	Decrease, ATPase activity
2180	Decrease, ATPase activity	leads to	Increase, Abnormal osmoregulation
2181	Increase, Abnormal osmoregulation	leads to	Increase, Tissue/organ damage
2182	Decrease, Coupling of OXPHOS	leads to	Increase, Complex III dysfunction
2183	Increase, Complex III dysfunction	leads to	Increase, Cyt c release
2184	Increase, Cyt c release	leads to	Increase, Apoptosis
2185	Increase, Apoptosis	leads to	Increase, Tissue/organ damage
2186	Increase, Complex III dysfunction	leads to	Increase, ROS production
2187	Increase, ROS production	leads to	Increase, Apoptosis
2188	Decrease, Coupling of OXPHOS	leads to	Increase, Complex I dysfunction
2189	Increase, Complex I dysfunction	leads to	Increase, ROS production
2190	Increase,Oxidative DNA damage	leads to	Apoptosis
2191	Apoptosis	leads to	Increase, Tissue/organ damage
2192	Reactive Metabolite	leads to	Mitochondrial dysfunction
2193	Mitochondrial dysfunction	leads to	Apoptotic cell death
2194	Reactive Metabolite	leads to	Immune cell activation
2195	Mitochondrial dysfunction	leads to	ER stress
2196	Immune cell activation	leads to	IFNγ signaling
2197	IFNγ signaling	leads to	Increase in inflammation
2198	Apoptotic cell death	leads to	Increase in inflammation
2199	Increase in inflammation	leads to	hepatitis
2200	ER stress	leads to	Apoptotic cell death
2201	Antagonism, Androgen receptor	leads to	Altered, Transcription of genes by AR
2202	Covalent Binding, Protein	leads to	Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
2203	Decrease, Coupling of OXPHOS	leads to	Decrease, ATP pool
2204	Decrease, ATP pool	leads to	Decrease, Cell proliferation
2205	Decrease, Cell proliferation	leads to	Decrease, Growth
2206	Increase, LPO	leads to	Decrease, Lipid storage
2207	Decrease, Lipid storage	leads to	Decrease, FAO
2208	Decrease, FAO	leads to	Decrease, ATP pool
2209	Decrease, ATP pool	leads to	Decrease, Oogenesis
2210	Increase, LPO	leads to	Increase, Apoptosis
2211	Increase, Follicular atresia	leads to	Decrease, Fecundity
2212	Reduced, Swimming performance	leads to	Increased Mortality
2213	Reduced, Posterior swim bladder inflation	leads to	Increased Mortality
2214	Decrease, ATP pool	leads to	Increase, Cell death
2215	Increase, Cell death	leads to	Decrease, Growth
2216	Decrease, ATP pool	leads to	Increase, Fatty acid β-oxidation
2217	Increase, Fatty acid β-oxidation	leads to	Decrease, Lipid storage
2218	Decrease, Lipid storage	leads to	Decrease, Growth
2219	Decrease, Coupling of OXPHOS	leads to	Increase, Oxygen consumption
2220	Increase, Oxygen consumption	leads to	Increase, ROS production
2221	Increase,Oxidative DNA damage	leads to	Increase, Cell death
2222	Increase, LPO	leads to	Increase, Cell death
2223	Increase, Protein oxidation	leads to	Increase, Cell death
2224	N/A, Mitochondrial dysfunction 1	leads to	Increase, ROS production
2225	Increase, ROS production	leads to	Increase, Global methylation
2226	Increase, Global methylation	leads to	Increase, Apoptosis
2227	N/A, Mitochondrial dysfunction 1	leads to	Increase, ROS
2228	N/A, Mitochondrial dysfunction 1	leads to	Decrease, ATP pool
2229	Increase, Mitochondrial ATP synthase antagonism	leads to	Decrease, ATP pool
2230	Increase, Mitochondrial complex III antagonism	leads to	Decrease, ATP pool
2231	Reduced, Hearing	leads to	Increased Mortality
2232	Inhibition, Na+/I- symporter (NIS)	leads to	T4 in serum, Decreased
2233	Inhibition, Iodotyrosine deiodinase (IYD)	leads to	Decreased, Thyroxine (T4) in serum
2234	Decreased, Thyroxine (T4) in serum	leads to	Altered, Amphibian metamorphosis
2235	Induction, Upregulation of glucuronyltransferase activity	leads to	Increase, Biliary excretion TH glucuronide
2236	Increase, Biliary excretion TH glucuronide	leads to	T4 in serum, Decreased
2237	Increased, Hepatic thyroid hormone uptake/transport	leads to	T4 in serum, Decreased
2238	Decreased, Triiodothyronine (T3) in tissues	leads to	Increased, Thyroid-stimulating hormone (TSH)
2239	Decreased, Triiodothyronine (T3) in tissues	leads to	Altered, TH-dependent gene expression
2240	Increased, Thyroid-stimulating hormone (TSH)	leads to	Increased, Thyroxine (T4) in serum
2241	Increased, Thyroxine (T4) in serum	leads to	Altered, Amphibian metamorphosis
2242	Increased, Thyroxine (T4) in serum	leads to	Altered, TH-dependent gene expression
2243	Increased, Triiodothyronine (T3) in tissues	leads to	Altered, TH-dependent gene expression
2244	Altered, TH-dependent gene expression	leads to	Altered, Amphibian metamorphosis
2245	Binding, Transthyretin in serum	leads to	Displacement, Serum thyroxine (T4) from transthyretin
2246	Displacement, Serum thyroxine (T4) from transthyretin	leads to	Increased, Free serum thyroxine (T4)
2247	Increased, Free serum thyroxine (T4)	leads to	Increased, Hepatic thyroid hormone uptake/transport
2248	Binding, Transthyretin in serum	leads to	Displacement, Serum thyroxine (T4) from carrier protein
2249	Displacement, Serum thyroxine (T4) from carrier protein	leads to	Increased, Free serum thyroxine (T4)
2250	Binding, Thyroid binding globulin in serum	leads to	Displacement, Serum thyroxine (T4) from carrier protein
2251	TLR4 activation	leads to	AP-1 activation
2252	Activation, PPARα	leads to	Increase, cell proliferation (hepatocytes)
2253	Activation, PPARα	leads to	Increase, hepatocellular adenomas and carcinomas
2254	Increase, cell proliferation (hepatocytes)	leads to	Increase, hepatocellular adenomas and carcinomas
2255	Inhibition of LS function.	leads to	Loss of alveolar capillary membrane integrity
2256	Inhibition of LS function.	leads to	Reduced lung volume
2257	Reduced lung volume	leads to	Immediate adverse lung effects
2258	Loss of alveolar capillary membrane integrity	leads to	Immediate adverse lung effects
2259	Loss of alveolar capillary membrane integrity	leads to	Substance - LS interaction
2260	Agonism, Androgen receptor	leads to	Increased, Differentiation to Testis
2261	Activation, Glucocorticoid Receptor	leads to	Up Regulation, CD36
2262	Up Regulation, CD36	leads to	Increased, Fatty acid uptake
2263	Increased, Fatty acid uptake	leads to	Increased, Liver Steatosis
2264	Decreased, Mitochondrial Fatty Acid Beta Oxidation	leads to	Accumulation, Triglyceride
2265	Accumulation, Triglyceride	leads to	Increased, Liver Steatosis
2266	Activation, Glucocorticoid Receptor	leads to	Decrease, ACAD
2267	Decrease, ACAD	leads to	Decreased, Mitochondrial Fatty Acid Beta Oxidation
2268	Increased, Free serum thyroxine (T4)	leads to	Increased, Uptake of thyroxine into tissue
2269	Binding, Transthyretin in serum	leads to	Increased, Clearance of thyroxine from serum
2270	Increased, Clearance of thyroxine from serum	leads to	T4 in serum, Decreased
2271	Binding, Transthyretin in serum	leads to	Increased, Free serum thyroxine (T4)
2272	Increased, Free serum thyroxine (T4)	leads to	Increased, Clearance of thyroxine from serum